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Abstract
In this thesis we used computational models based on cellular automata and
the abstract model of cancer hallmarks to analyze the emergent behavior of
tumor growth at cellular level. Tumor growth is modeled with a cellular auto-
maton which determines cell mitotic and apoptotic behaviors. These behaviors
depend on the cancer hallmarks acquired in each cell as consequence of muta-
tions. The presence of the cancer hallmarks defines cell states and cell mitotic
behaviors. Additionally, these hallmarks are associated with a series of para-
meters, and depending on their values and the activation of the hallmarks in
each of the cells, the system can evolve to different dynamics.
With the simulation tool we performed an analysis of the first phases of
cancer growth. Firstly, we studied the evolution of cancer cells and hallmarks
in different representative situations regarding initial conditions and paramet-
ers, analyzing the relative importance of the hallmarks for tumor progression;
Secondly, we focused on the analysis of the effect of killing cancer cells, in-
specting the time evolution of the multicellular system under such conditions
and the possible behavioral transitions between the predominance of cancer
and healthy cells.
Later, we analyzed the effect of treatment applications on cancer growth
taking into account the presence of Cancer Stem Cells (CSCs) and their re-
growth capacity. Finally, we used evolutionary computing to analyze the im-
plications of treatment strategies in a CSC context. In this way, we determined
the best strategies of treatment applications in terms of intensity, duration and
periodicity considering the regrowth capacity of CSCs.
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The thesis deals with the modeling of tumor growth, considering this as an
emergent consequence of the interactions between cells and their environment.
The state of a cell will depend on a number of characteristic features of cancer
and its immediate surroundings, which defines the state of a cell and its mitotic
behavior.
Cancer is currently considered a very complex phenomenon consistent of
numerous and different diseases, each of them with different and multifactorial
causes (being the genetic ones only one type among others such as environ-
mental, occupational, nutritional or even viral). Although there are more than
200 different types of cancer that can affect every organ in the body, they share
certain features. Thus, Hanahan and Weinberg described the phenotypic dif-
ferences between healthy and cancer cells in a landmark article entitled “The
Hallmarks of Cancer” [39]. The six essential alterations in cell physiology that
collectively dictate malignant growth are: self-sufficiency in growth signals,
insensitivity to growth inhibitory signals, evasion of programmed cell death
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue
invasion and metastasis, that are detailed later.
This thesis will consider this model of hallmarks, thus placing us in the
study of the multicellular system behavior at the cellular level, without the
need of a detailed knowledge of the molecular, genetic or epigenetic lower
levels. That is, our modeling considers this abstract scheme that takes into
account the presence of the hallmarks acquired by the cells. This abstract
model is sufficient for our aim focused on the analysis of the behavior of the
multicellular system at that cellular level. But given the interrelations among
the hallmarks and their dependence on their defining parameters (like hall-
mark mutation probability, initial telomere length, ... described later), the
behavior obtained in the multicellular system is impossible to infer intuitively
or analytically. This modeling can help us to test novel hypotheses, confirm in
vitro experiments and simulate the dynamics of complex systems in a relatively
fast time without the enormous costs of laboratory experiments.
One of the traditional approaches to model cancer growth was the use of
2 Chapter 1. Introduction
differential equations to describe avascular, and indeed vascular, tumor growth
[76]. For example, the kinetic models of clonal expansion [7][21][103] allowed
to include and analyze specific cancer conditions. As indicated by Wodarz and
Komarova [102], referring to the modeling with ordinary differential equations
(ODE) “Among the advantages is its simplicity. The disadvantages include
the absence of detail. For instance, no spatial interactions can be described
by ODEs, thus imposing the assumption of mass-action-type interactions”.
Moreover, as indicated by Enderling et al. [24] these approaches tend to rep-
resent tumor cells collectively by a single proliferation term and a death term,
including more optional specialized functionalities like interaction of tumor
cells with their local environment [24]. Also, many models presuppose that all
cancer cells have acquired the same hallmarks. Moreover, if partial differential
equations (PDE) are used, as the again Wodarz and Komarova state “there is
one obvious limitation of PDEs which comes from the very nature of differen-
tial equations: they describe continuous functions. If the cellular structure of
an organ is important, then we need to use a different method” [102].
Cancer can be viewed, from the standpoint of the Artificial Life discipline
[2][52], as an ecological system in which cells with different mutations com-
pete for survival [94]. Moreover, tumor growth in multicellular systems is an
example of emergent behavior, which is present in systems whose elements in-
teract locally, providing global behavior which is not possible to explain from
the behavior of a single element, but rather from the “emergent” consequence
among the interactions of the group [2][52]. In this case, it is an emergent
consequence of the local interactions between the cells and their environment.
Emergent behavior was studied in Artificial Life and Complex Systems Theory
[2][52] using models like Cellular Automata (CA) and Lindenmayer Systems
[46][51][52]. CA have been the focus of attention because of their ability to
generate a rich spectrum of complex behavior patterns out of sets of relatively
simple underlying rules and they appeared to capture many essential features
of complex self-organizing cooperative behavior observed in real systems [46].
The advantage of the CA models is that these can directly incorporate the
rules that define the mitotic and apoptotic behaviors from the direct definition
of the hallmarks. As indicated by Basanta et al. [11] “CA models allow the
study of emergent processes in which space is an important feature and in
which the behavior of individual agents can be described by rules”. This is
the case in the modeling of the rules of apoptotic and mitotic behaviors based
on the presence of cancer cell hallmarks. There are also hybrid approaches in
which the automaton combines discrete and continuous fields (modeled with
ODEs), such as the work by Ribba el al. [82] using a hybrid cellular automaton,
which incorporates nutrient and drug spatial distribution (these modeled with
differential equations). As our aim is to model cell behavior at cellular level
based on the presence of the hallmarks in each individual cell, we also used
the CA approach.
1.2. Previous works using cellular automata for tumor growth modeling 3
1.2 Previous works using cellular automata for tu-
mor growth modeling
There are several previous works using CA models for different purposes in the
modeling of tumor growth. The work of Rejniak and Anderson [80] summarizes
different alternatives, and here we comment some examples. Bankhead and
Heckendorn [10] used a cellular automaton which incorporated a simplified ge-
netic regulatory network simulation to control cell behavior and predict cancer
etiology. Their simulation used known histological morphology, cell types, and
stochastic behavior to specifically model ductal carcinoma in situ (DCIS), a
common form of non-invasive breast cancer. The results of the authors showed
that a contributing factor to the different pathology of hereditary breast can-
cer comes from the ability of progenitor cells to pass cancerous mutations on
to offspring.
Ribba et al. [82] used a hybrid cellular automaton, “hybrid” because the
automaton combines discrete and continuous fields, as it incorporates nutrient
and drug spatial distribution together with a simple simulation of the vascular
system in a 2-dimensional lattice model. The authors presented an application
of the model for assessing chemotherapy treatment for non-Hodgkin’s lymph-
oma (NHL). Alarco´n et al. [5] used this model to study how blood flow and
red blood cell heterogeneity influence the growth of systems of normal and
cancer cells.
Gerlee and Anderson [30] presented a cellular automaton model of clonal
evolution in cancer aimed at investigating the emergence of the glycolytic
phenotype (cells uses an oxygen independent metabolic pathway, meaning that
it does not use molecular oxygen for any of its reactions to produce ATP
and lactic acid directly from glucose) and which acted in a two-dimensional
grid. In their model each cell was equipped with a microenvironment response
network that determined the behavior or phenotype of the cell based on the
local environment. The response network was modeled using a feed-forward
neural network, which was subject to mutations when the cells divided. This
implies that cells might react differently to the environment and when space
and nutrients are limited only the fittest cells survive. With this model they
investigated the impact of the environment on the growth dynamics of the
tumor. For low oxygen concentration they observed tumors with a fingered
morphology, while increasing the matrix density gave rise to more compact
tumors with wider fingers. The distribution of phenotypes in the tumor was
also affected, as the glycolytic phenotype was most likely to emerge in a poorly
oxygenated tissue with a high matrix density.
In the two-dimensional CA model of Ghaemi et al. [32] the authors determ-
ined thresholds for the nutrient concentration to establish the probabilities of
a cancer cell remaining in that state or dying from necrosis, as well as for de-
termining whether a healthy cell proliferates or it is replaced by a cancer cell.
Gevertz et al. [31] adapted a previous CA model developed by the authors (de-
signed to simulate spherically symmetric tumor growth) to study the impact
of organ-imposed physical confinement and heterogeneity on tumor growth,
that is, to incorporate the effects of tissue shape and structure. The results of
the authors indicate that the impact is more pronounced when a neoplasm is
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growing close to, versus far from, the confining boundary.
On the contrary to the diverse examples of CA for modeling tumor growth,
there are very few previous works which have used the model of hallmarks. For
example, in the work of Basanta et al. [11], the authors used a two-dimensional
cellular automaton that modeled key cancer cell capabilities based on the Ha-
nahan and Weinberg hallmarks. They focused their work on analyzing the
effect of different environmental conditions on the sequence of acquisition of
phenotypic traits. Their results showed that microenvironmental factors such
as the local concentration of oxygen or nutrients and cell overcrowding may
determine the expansion of the tumor colony. The results also showed that
tumor cells evolve and that their phenotypes adapt to the microenvironment
so environmental stress determines the dominance of particular phenotypic
traits.
Abbott et al. [1] also investigated the dynamics and interactions of the
Hanahan and Weinberg hallmarks in a CA model the authors called Cancer-
Sim. The main interest of the authors with their simulation was to describe
the likely sequences of precancerous mutations or pathways that end in cancer.
They were interested in the relative frequency of different mutational pathways
(what sequences of mutations are most likely), how long the different path-
ways take, and the dependence of pathways on various parameters associated
with the hallmarks. Using the same modeling, Spencer et al. [94] explored
the timing of cancer onset, the order in which mutations are acquired, the di-
versity of tumours, and the competition and cooperation between cells in the
tumor microenvironment, providing insight into how the sequence of acquired
mutations affects the timing and cellular makeup of the resulting tumor.
Butler [14] studied the impact of hallmarks during the early growth stages
of solid tumor development with a hybrid model that combines a discrete model
of cancer cells using cellular automata, with a continuous model of blood flow
using lattice Boltzmann methods. Hallmarks were removed in pairs, triplets
and quadruplets in order to model combination therapies, abstracting drugs
that target these properties as the removal of the hallmark from the system. It
was found that not all combinations are equally effective, even if the individual
treatments are effective. In fact, many combinations had no effect on tumor
growth. However, in general, as more treatments were applied, cancer growth
decreased.
We applied a 3D Cellular Automaton algorithm to model cancer growth
behavior. This model mimics the development in vitro of multicellular spher-
oids of tumor cells. In vitro three-dimensional tumor spheroids are spherically
symmetric aggregates of cells analogous to tissues, with no artificial substrate
for cell attachment. Recently, these tumor spheroids have gained relevance as
model of solid tumors. As indicated by Phung et al. [77], the three-dimensional
spheroids exhibit many features of the tumor microenvironment and model the
avascular region of tumors that is dependent on diffusion, and these models
have begun to be included in toxicologic tests and evaluation of therapeutic
strategies.
In our proposal the CA rules will be designed to model the mitotic and
apoptotic behaviors in each cell from the information of the cell state and from
its surrounding environment. We will define the rules from the main behavior
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of the cells when the main hallmarks are present in the cells. As commented,
Abbott et al.’s work [1], focused on possible pathways or sequences of hallmark
mutations that end in cancer, and Basanta et al.’s work [11], focused on the
influence of microenvironmental factors on tumor expansion, also used models
based on the Hanahan and Weinberg hallmarks. Here, our aim is different,
as our modeling and simulation will try to determine the dependence of the
multicellular system behavior, at cellular level, on the presence of the different
cancer cell hallmarks and their key defining parameters. We experimented
with different conditions, not previously considered, that have implications for
cell population dynamics and which are difficult to foresee without a model and
associated simulating tool. We have focused our work on the study of possible
behavioral regime transitions between states with predominance of one type of
cells and on the dependence of the emergent tumor growth behavior on each
individual hallmark, studying their relative importance in tumor development.
The effects of Cancer Stem Cells are also included in the modeling, with their
tumor regrowth capability. We have not considered in our study the effects of
the concentration of oxygen or nutrients, as these factors are not relevant for
our focus on the dependence of the cell behavior on the main hallmarks and
in the avascular phase analyzed.
1.3 The biology of cancer
Cancer is a group of diseases characterized by out-of-control cell growth. Thus,
cancer cells divide without control and are able to invade other tissues causing
metastasis. There are more than 200 different types of cancer, and each is
classified by the type of cell that is initially affected as well as the affected
organs. Normal body cells grow and divide and know to stop growing. Over
time, they also die. Unlike these normal cells, cancer cells just continue to
grow and divide out of control and do not die when they are supposed to.
The great majority of cancers (90–95% of cases) are due to environmental
factors such as lifestyle, behavioral factors, pollution, etc. The remaining
5–10% are due to inherited genetics (the genetic predisposition is inherited
from family members) [6]. That is, it is possible to be born with certain
genetic mutations or a fault in a gene that makes one statistically more likely
to develop cancer later in life.
There are six broad groups that are used to classify cancer [72].
• Carcinomas: characterized by cells that cover internal and external parts
of the body such as breast, lung and colon cancer.
• Sarcomas: characterized by cells that are located in bone, cartilage,
muscle, connective tissue, and other supportive tissues.
• Lymphomas: cancers that begin in the lymph nodes and immune system
tissues.
• Leukemias: cancers that begin in the bone marrow and often accumulate
in the bloodstream.
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• Adenomas: cancers that arise in the thyroid, the adrenal gland, the
pituitary gland and other glandular tissues.
• Mixed types: cancers with components that belong to different previous
categories. Some examples are: carcinosarcoma (malignant tumor that
is a mixture of carcinoma and sarcoma, which can affect to different
organs like utero, stomach or lungs) or adenosquamous carcinoma (type
of cancer that contains two types of cells: squamous cells and gland-like
cells, which affect to different organs like lungs or pancreas).
1.4 The hallmarks of cancer
Hanahan and Weinberg described the phenotypic differences between healthy
and cancer cells in an article entitled “The Hallmarks of Cancer” [39] and
its update in 2011 [40]. The six essential alterations in cell physiology that
collectively dictate malignant growth are: self-sufficiency in growth signals, in-
sensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed
cell death (apoptosis), limitless replicative potential, sustained angiogenesis,
and tissue invasion and metastasis. In other words, these alterations provide
the cell with an advantage due to increased proliferation capabilities, decreased
death, the ability to induce angiogenesis or enhanced migration and invasion.
Once a cell has evolved a sufficiently aggressive phenotype, it can escape from
homeostatic control mechanisms and initiate tumorigenesis. In a recent update
[40] the authors included two more hallmarks: reprogramming of energy meta-
bolism and evasion of immune destruction, that emerged as critical capabilities
of cancer cells. Moreover, the authors described two enabling characteristics
or properties of neoplastic cells that facilitate acquisition of hallmark capab-
ilities: genome instability and tumor-promoting inflammation (mediated by
immune system cells recruited to the tumor site).
Below the different hallmarks used in the modeling in the avascular phase
are described.
• Self-sufficiency in growth signals (SG, Self-Growth): Normal cells need
external growth signals called growth factors to grow and divide. When
the growth signals are not present, they stop growing. However, cancer
cells do not require stimulation from external signals to multiply. Thus,
they can grow and divide without external growth signals. Actually, cells
can either produce their own growth hormones or they have changed so
that they behave as if growth factors were present even in the absence
of growth hormones.
• Insensitivity to anti-growth signals (IGI, Ignore Growth Inhibit): This
hallmark refers to the inability to respond normally to signals that regu-
late growth. In normal tissue, proliferation is blocked by powerful negat-
ive regulators that control cell division. These inhibitors act on the cell
cycle clock, by interrupting cell division in the interphase (see section
1.5). Cancer cells become insensitive to these anti-growth signals. As
the tumor expands, it squeezes adjacent tissue, which sends out chemical
messages that would normally bring cell division to a halt. Malignant
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Figure 1.1: Schematic view of the initial hallmarks considered in [39][40]. Fig-
ure reprinted with permission from Elsevier.
cells ignore the commands, proliferating despite anti-growth signals is-
sued by neighboring cells. This may be because tumor suppressor genes
such as Rb, p53 or TP53 may be inactivated, or contact inhibition mech-
anisms may be evaded.
• Evading apoptosis (EA): Apoptosis is a form of programmed cell death,
the mechanism by which cells are programmed to die in the event they
become damaged. Cancer cells must overcome apoptosis to progress.
The p53 tumor suppressor protein and gene elicits apoptosis in response
to DNA damage, and is a major mechanism of cancer control. In order
for cancer to progress, it must overcome p53, and p53 is mutated in more
than 50 percent of cancers.
• Limitless replicative potential (EI, Effective Immortality): Healthy cells
can divide no more than several times (< 100). The Hayflick limit [41]
is the number of times a normal human cell can divide until cell divi-
sion stops. The limited replicative potential arises because, with the
duplication, there is a loss of base pairs in the telomeres (chromosome
ends which protect the bases), so when the DNA is unprotected, the cell
dies. Malignant cells overproduce the telomerase enzyme, avoiding the
telomere shortening, so such cells overcome the reproductive limit.
• Genetic instability (GI): It is an additional factor that accounts for the
high incidence of mutations in cancer cells [1]. It is an enabling charac-
teristic of cancer [40] since, while not necessary in the progression from
neoplasm to cancer, makes such progression much more likely [11].
• Sustained angiogenesis (AG): Angiogenesis is the process by which new
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Figure 1.2: The effect of angiogenesis in tumor growth. A: When a tumor
is small, cancer cells obtains oxygen and nutrients from surrounding blood
vessels. B: As the tumor grows beyond the capacity of local blood vessels,
soluble pro-angiogenic growth factors are released which promote the sprouting
of new vessels (neovascularization) from local pre-existing blood vessels. C:
The new vessels provide a blood supply for the tumor enabling tumors to grow
beyond 2–3mm3 in size.
blood vessels are formed. Cancer cells initially lack angiogenic ability,
limiting their capability to expand. In order to progress, they must de-
velop blood supply for ensuring that such cells receive a continual supply
of oxygen and other nutrients (Figure 1.2). They obtain them by co-
opting nearby blood vessels with growth induction of new branches that
run throughout the growing mass. Angiogenic capability is the result
of a balance between pro-angiogenic (VEGF, acidic and basic fibroblast
growth factors) and anti-angiogenic factors (trombospondin-1).
• Tissue invasion and metastasis: Although uncontrolled cell growth and
division is what most people associate with cancer, tissue invasion and
metastasis (spreading) are what make many cancers lethal. In order for
cancer to spread, cells must acquire mutations that turn on genes which
allow them to break free from the primary tumor, travel through the
blood stream, and establish a new colony of cells at another site in the
body.
Different hallmarks are associated with different therapeutic agents as Fig-
ure 1.3 shows. The rapidly growing of targeted therapeutics can be categorized
according to their respective effects on one or more hallmark capabilities. In
fact, the observed efficacy of these drugs represents, in each case, a validation
of a particular capability: if a capability is truly important for the biology
of tumors, then its inhibition should harm tumor growth. Drugs that gum
up with each of the acquired capabilities necessary for tumor progression have
been developed and are in clinical trials or, in some cases, approved for clinical
use in treating certain forms of human cancer [40].
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Figure 1.3: Terapeutic Agents. Figure from [40], reprinted with permission
from Elsevier.
1.5 Cell cycle
The cell cycle is an ordered set of events that take place in a cell leading to its
division and duplication. In cells with a nucleus the cell cycle can be divided
in three periods: quiescent (G0 phase), interphase and the mitotic phase:
• The G0 phase is a resting phase where the cell has left the cycle and has
stopped dividing.
• In the interphase, the cell is constantly synthesizing RNA, producing
proteins and growing in size. Interphase can be divided into 3 steps:
Gap 1 (G1), S (synthesis) phase, Gap 2 (G2).
– The G1 phase: Cells increase in size in Gap 1, produce RNA and
synthesize proteins. An important cell cycle control mechanism ac-
tivated during this period (G1 Checkpoint) ensures that everything
is ready for DNA synthesis.
– The S phase: To produce two similar daughter cells, the complete
DNA instructions in the cell must be duplicated. DNA replication
occurs during this S (synthesis) phase.
– In the G2 phase the cell continues to grow and to produce new
proteins. At the end of this gap there is another control checkpoint
(G2 Checkpoint) to determine if the cell can now proceed to enter
phase M (mitosis) and divide.
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• The mitotic phase consists of nuclear division. Cell growth and protein
production stop at this stage in the cell cycle. All of the cell’s energy is
focused on the complex and orderly division into two similar daughter
cells. Mitosis is much shorter than interphase, since it is a relatively short
period of the cell cycle. There is a Checkpoint in the middle of mitosis
(Metaphase Checkpoint) that ensures the cell is ready to complete cell
division.
Figure 1.4 shows a schematic view of the cell cycle.
Figure 1.4: Phases of the cell cycle. Figure reprinted with permission by
Siyavula Education and made available at www.everythingscience.co.za
under the terms of a CC-BY 3.0 license [60].
1.6 Cell pathways
Many genes can be involved in a single cellular process. These genes are often
organized into pathways. A pathway is the coordinated interaction of several
proteins that are responsible for a particular component of a cell function. A
pathway can be viewed as an electrical circuit. The pathway passes a signal
in a particular order between proteins like a pulse of electricity traveling down
a wire (passing on a phosphate group from one protein to another). When a
protein is bound to a phosphate group, it is able to bind to the next protein
in the pathway. It then hands off its phosphate group, and now this second
protein is able to bind to the next protein in the series, and so on. This process
is called phosphorylation.
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Figure 1.5: The PI3K/Akt/mTOR signaling pathway [54]. This pathway is
up-regulated in a significant proportion of ovarian cancers. Figure reprinted
with permission from InTech.
Many solid cancers exhibit a deregulation of different oncogenic pathways.
In the last years, many genes responsible for the genesis of different cancers
have been discovered, their mutations identified, and the pathways through
which they act characterized. A single mutated protein in a pathway can
cause uncontrolled growth and cause cancer. “Targeted” cancer drugs are
designed to block abnormal pathways. By blocking an overactive pathway, the
drugs can slow a cancer’s growth and order malignant cells to self-destruct.
Unfortunately, cancer cells can “learn” to activate other pathways, so that the
original target drug is no longer effective by itself. Thus, the next step is to
try to fight back by using combinations of drugs that attack multiple broken
pathways.
In Figure 1.5 an example of cancer pathway called PI3K/Akt/mTOR path-
way [54] is illustrated. This is is an intracellular signaling pathway important
in regulating the cell cycle. It is directly related to cellular quiescence, prolif-
eration, cancer, and longevity. PI3K activation phosphorylates and activates
AKT, localizing it in the plasma membrane. AKT can have a number of
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downstream effects such as activating mTOR which regulates cell growth by
controlling mRNA translation, ribosome biogenesis, autophagy, and metabol-
ism [35]. Several studies have identified this pathway as the most frequently
altered in different types of cancer [45][75][100].
As we indicated in the subsections about motivation and hallmarks, a hall-
mark is an abstraction which can be activated as consequence of different
malfunctions in the components of a pathway or pathways. Since our aims are
focused on the study of the multicellular system behavior depending on the
hallmarks acquired in the cells we will not consider the details of genes and
proteins in the associated pathways.
1.7 Cancer stem cells
The cancer stem cell theory suggests that tumor cells include a minority popu-
lation of cells responsible for the initiation of tumor development, growth, and
tumor’s ability to metastasize and reoccur [25][34]. Cancer stem cells (CSCs)
are cancer cells that possess features associated with normal stem cells, spe-
cifically the ability to give rise to all cell types found in a particular cancer
sample. Such cells are proposed to persist in tumors as a distinct population
and cause relapse and metastasis by giving rise to new tumors [8].
Therefore, development of specific therapies targeted at CSCs holds hope
for improvement of survival and quality of life of cancer patients, especially for
patients with metastatic disease. The existence of CSCs has several implica-
tions in terms of future cancer treatment and therapies. These include disease
identification, selective drug targets, prevention of metastasis, and develop-
ment of new intervention strategies. Thus, different works tried to simulate
their behavior, taking into account their main characteristics, such as their
capacity to divide indefinitely [103]. If current treatments of cancer do not
properly destroy enough CSCs, the tumor will reappear, so it is important to
understand their behavior and effects.
There are two models when considering the origin of cancer cells: The hier-
archical model assumes that tumors are originated from CSCs that give rise to
progeny with self-limited proliferative capacity where most of the cells in the
tumor are genetically homogeneous. The second model is the stochastic model
or clonal evolution model, which postulates that tumorigenesis is a multi-step
process that leads to progressively genetic alterations with the transformation
of healthy cells into malignant phenotypes [104]. Thus, two models have been
considered for explaining the origin of cancer cells: In the hierarchical CSC
model, CSCs can divide either symmetrically to yield two CSCs, or asymmet-
rically to produce a CSC and a non-stem cancer cell with limited proliferation
capacity (Differentiated Cancer Cell, DCC). These concepts will be exposed
in better detail in chapter 4.
Figure 1.6 illustrates the problem with the presence of CSCs. If a standard
treatment do not destroy the CSC population, there will be a regrowth of the
tumor. This problem will be considered in chapters 5 and 6.
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Figure 1.6: In the Cancer Stem Cell (CSC) model these cells can divide sym-
metrically or asymmetrically to produce Differentiated Cancer Cells (DCCs)
with limited proliferative capability.
1.8 Organization of the thesis
This thesis describes the cancer growth model developed and the analysis of
the simulation results. In the following paragraphs a short summary of each
chapter is provided.
Chapter 2 describes the event model used for simulating the behavior of the
multicellular system through time. The simulation algorithm is explained and
different exploratory initial simulations using the event model are presented.
In Chapter 3 the relevance of hallmarks is studied in different representative
situations of the first phases of cancer growth. Moreover, potential behavior
transitions in tumor growth dynamics are analyzed when a treatment is applied
in different scenarios defined by the relative prevalence of different hallmarks.
Chapter 4 focuses on the simulation of the behavior of cancer stem cells to
inspect their capability of regeneration of tumor growth in different scenarios.
The analyses of the capabilities of the hallmarks to promote tumor growth
serve also to test their capabilities in a cancer stem cell context.
In Chapter 5 the effect of cancer treatments in a cancer stem cell context is
analyzed. The application of a standard treatment in a cancer stem context has
consequences on tumor regrowth behavior. Therefore, different strategies when
a treatment is applied will be analyzed by taking into account the implications
of CSC presence.
In Chapter 6 evolutionary computing is used to optimize a treatment in
terms of intensity, duration and periodicity taking into account the presence
and effects of cancer stem cells. We selected for our objective Differential
Evolution as a robust evolutionary method.
Finally, in Conclusions we discuss and summarize the main conclusions,
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together with ideas about possible future research lines related with the work
of this thesis.
Chapter 2
Event model for tumor growth
simulation
2.1 Event model
We used an event model for simulating the behavior of the multicellular sys-
tem through time, which is oriented to the modeling of the cell cycle taking
into account the presence of the hallmarks in the cells. We used the event
model introduced by Abbott et al. [1], which uses an event queue for storing
possible future mitotic events. Moreover, each cell resides in a site in a 3D
grid environment. In the modeling, each cell genome indicates if any hallmark
is activated as consequence of mutations.
On the contrary to Abbott et al.’s work [1], in our case metastasis and
angiogenesis are not considered, as we are interested in the first avascular
phases of tumorigenesis. So, every cell has its “genome” which consists of five
hallmarks with a binary representation indicating if each one of the hallmarks
(Self Growth-SG, Ignore Growth Inhibit-IGI, Evade Apotosis-EA, Effective
Inmortality-EI and Genetic Instability-GI) is activated, in addition to some
parameters particular to each cell. These parameters are related with each of
the hallmarks considered and the behavior of the cells when the hallmarks are
acquired in a cell.
The parameters are briefly defined in Table 2.1, whereas in next subsections
the implications of the parameters in the multicellular system behavior will be
explained.
In the simulation of the cell life cycle, most elements do not change observ-
ably each time step. The only observable changes to cells are apoptosis and
mitosis. In a tissue, only a fraction of all cells are undergoing such transitions
at any given time. The different phases of the cell cycle explained in Section
1.5 are simulated in a simple way. The G0 phase is triggered by contact in-
hibition. Thus, cells with a full set of neighbors normally do not attempt to
replicate. Cells next to empty space within the tissue’s natural extent auto-
matically enter the G1 phase. G1 is modeled by the passage of time; each
cell occupies equal volume, and the physical enlargement of cell growth is not
simulated. DNA replication occurs in the S phase. The replication of DNA
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Table 2.1: Definition of the parameters associated with the hallmarks
Parameter name Defaultvalue Description
Grid size The number of cells in the 3D lattice for thesimulation.
Hallmark mutation
rate (1/m) 10
5 Each gene (hallmark) is mutated (when the
cell divides) with a 1/m chance of mutation.
Telomere length
(tl) 50
Initial telomere length in each cell. Every time
a cell divides, the length is shortened by one
unit. When it reaches 0, the cell dies, unless
the hallmark EI is ON.
Evade apoptosis (e) 10
A cell with n hallmarks mutated has an extra
n/e likelihood of dying each cell cycle, unless




There is an increase of the hallmark mutation




Cells with the hallmark “Ignore growth in-
hibit” (IGI) activated have eliminated the in-
hibition by contact. For the modeling, as in
[1][94], these cells have a probability 1/g of




3 In each cell cycle every cell has a 1/a chance
of death from several causes.
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occasionally introduces a mutation that will be inherited by daughter cells.
Then, at the G2 checkpoint, cells undergo a check for genetic damage. Apop-
tosis is triggered in cells found to contain genetic defects. The G1 checkpoint is
not modeled separately, because it is similar (This checkpoint prevents prepar-
ation for DNA replication until the detected DNA damage has been removed).
Finally, the cell undergoes mitosis in the M phase. One of the daughter cells
occupies the grid location of its parent, while the other fills an empty adjacent
location.
Algorithm 2.1.1 summarizes the simulation, which takes into account the
main aspects of the cell cycle from the application point of view, specifying the
order for testing the implications of the different hallmarks in the simulated
cell cycle (TESTS 1 to 5).
Figure 2.1 represents graphically the algorithm in order to explain the
procedure more clearly. The process is simulated as a event model where
a mitosis is scheduled several times in the future, being a random variable
distributed uniformly between 5 and 10 time steps (see Figure 2.2). This is
done to simulate the variable duration of the cell life cycle (between 15 and 24
hours). Taking into account these time intervals, each time iteration represents
an average time of 2.6 hours, so, for example, 5000 iterations in the simulation
imply an average time of 77.4 weeks (1.48 years). Moreover, in the simulation,
a grid with 106 sites represents approximately 0.1 mm3 of tissue. The main
aspects of the model can be summarized in the following steps:
Start: The simulation can begin by initializing all elements of the grid to
represent empty space, as in most previous works [1][11][25][80]. Then,
the element at the center of the grid is changed to represent a single
normal cell (no mutations). Mitosis is scheduled for this initial cell (push
a mitotic event in the event queue between 5 and 10 time iterations in
the future).
After the new daughter cells are created, mitoses are scheduled for each
of them, and so on. Each mitotic division is carried out by copying
the genetic information (the hallmark status and associated parameters)
of the cell to an unoccupied adjacent space in the grid (a random free
site among the 26 immediate neighbors in the 3D grid). Random errors
occur in this copying process, so some hallmarks can be activated, taking
into account that once a hallmark is activated in a cell, it will be never
repaired by another mutation [1].
As an alternative, we will consider in our simulations an initial grid full
of healthy cells, being the process the same but scheduling the mitoses
for all the cells.
Pop event: The events are ordered on event time. Pop event from the event
queue with the highest priority (the nearest in time) (see Figure 2.2).
Random cell death test (Test 1): Cells undergo random cell death with low
probability (1/a chance of death). In each cell cycle, each cell is subjected
to a 1/a chance of death, where a is a tunable parameter. This might
be due to mechanical, chemical or radiological damage, aging, or the
immune system.
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Genetic damage test (Test 2): The larger the number of hallmark mutations,
the greater the probability of cell death. If “Evade apoptosis” (EA) is
ON, death as consequence of the genetic damage is not applied. This
corresponds with the G2 checkpoint of the cell cycle (see Section 1.5).
Mitosis tests:
1. Replicative potential checking (Test 3): If the telomere length is 0,
the cell dies, unless the hallmark “Effective immortality” (Limitless
replicative potential, EI) is mutated (ON).
2. Growth factor checking (Test 4): As in [1][11][94], cells can per-
form divisions only if they are within a predefined spatial boundary,
which represents a threshold in the concentration of growth factor;
beyond this area (95% of the inner space in each dimension in our
simulations, which represents 85.7% of the 3D grid inner space)
growth signals are too faint to prompt mitosis (unless hallmark SG
is ON).
3. Ignore growth inhibit checking (Test 5): If there are not empty cells
in the neighborhood, the cell cannot perform a mitotic division.
As in [1][94], if the “Ignore growth inhibit” hallmark (IGI) is ON,
then the cell competes for survival with a neighbor cell and with a
likelihood of success (1/g).
If the three tests indicate possibility of mitosis:
• Increase the hallmark mutation rate if genetic instability (GI) is ON.
That is, if the cell has this factor (GI) acquired then its mutation
rate is increase by a factor (i).
• Add mutations to the new cells according to the hallmark mutation
rate (1/m).
• Decrease telomere length in both cells.
• Push events. Schedule mitotic events (push in event queue) for both
cells: Mother and daughter, with the random times in the future.
If mitosis cannot be applied:
• Schedule a mitotic event (in queue) for mother cell.
2.1.1 Comments about hallmark parameters
There are two particular parameters, telomere length and hallmark mutation
rate, that can change their values in a particular cell over time, as explained in
Table 2.1. The cell’s genome is inherited by the daughter cells when a mitotic
division occurs. The default values indicated in Table 2.1 are the same as those
used in [1], except the initial telomere length and the higher value of g (which
defines the probability of escaping the contact inhibition mechanism) used by
us. In the case of the telomere length, we used the default value indicated in
Spencer et al. [94] as it corresponds to the Hayflick limit [41]. Nevertheless,
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Algorithm 2.1.1: Event model for cancer simulation()
t← 0 // Simulation time. Initial cell at the centre of the grid.
Schedule a Mitotic Event(5,10) // Schedule a mitotic event with a
// random time (ts) between 5 and 10 time iterations in the future
// (t+ts). The events are stored in an event queue. The events are
// ordered on event time.
while event in the event queue
do

Pop event( ) // Pop event with the highest priority (the nearest in time).
t← popped event time
TEST 1: Random cell death( ) // The cell can die with a given
// probability.
TEST 2: Genetic damage( ) // The larger the number of hallmark
// mutations, the greater the probability of cell
// death. If “Evade apoptosis” (EA) is ON, death
// is not applied.
Mitosis tests( ) :
TEST 3: Limitless replicative potential checking( )// If
// the telomere length is 0, the cell dies, unless the hallmark
// “Effective immortality” (Limitless replicative potential, EI) is ON.
TEST 4: Growth factor checking( ) // Cells can perform
// divisions only if they are within a predefined spatial boundary which
// sufficient growth factor; beyond this area cells cannot perform
// mitosis, unless the hallmark “Self-growth” (SG) is ON.
TEST 5: Ignore growth inhibit checking( ) // If there are not
// empty cells in the neighborhood, the cell cannot perform a mitotic
// division. If the “Ignore growth inhibit” hallmark (IGI) is ON, then
// the cell can perform the division with a given probability, replacing
// one of the neighbor cells.




// Increase the hallmark mutation rate if “Genetic instability”
// (GI) is ON.
// Add mutations to the new cells according to the hallmark
// mutation rate (1/m). Decrease telomere length in both cells.
Push events( )
// Schedule mitotic events (push in event queue) for both cells:
// mother and daughter, with the random times in the future.
else Push event( ) // Schedule a mitotic event in queue for mother cell.
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Figure 2.1: Diagram of the event model. The rectangles indicate an action,
a rhomb indicates a check with an associated binary question, as explained
in the text. This process is repeated to all the cells in the grid environment.
Each cell is represented with a small circle. If the cell dies after a check it is
represented with a crossed-circle.
Figure 2.2: Event model used in the simulation. Mitoses are scheduled between
5 and 10 time iterations in the future. When a mitosis event is processed,
several tests are performed to determine if the cell dies, continues quiescent or
can perform the division (explained in Figure 2.1 and Algorithm 2.1.1).
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the simulations can use greater values of the initial telomere length -as in [1]-,
being in this case the main limits for cell proliferation the area with growth
factors and the grid size.
Other parameters are more difficult to determine in order to have a dir-
ect analogy in nature. For example, as indicated by Spencer et al. [94], the
parameters g, e and a were chosen via a sensitivity analysis such that the
parameter plays an important role but does not dominate tumorigenesis or,
as indicated in [1], the choice of parameter values “was guided by the obser-
vation that hallmarks only have meaningful interactions within some region of
interest”. We used a standard value of g = 30, a greater value than the one
used in [1] (g = 10) and [94] (g = 5), implying a lower possibility of escaping
the contact inhibition mechanism, although we will reason about the resultant
behavior with different values.
The parameter m determines the probability of acquisition of a hallmark
when the cell divides (hallmark mutation rate 1/m). Bielas et al. [13] de-
veloped an assay to quantify random mutations in human tissue and their
results showed that, in normal tissues, the frequency of spontaneous random
mutations is exceedingly low, less than 10−8 per base pair. In contrast, tumors
exhibited an average frequency of 210 ·10−8 per base pair, an elevation of at
least two orders of magnitude. Nevertheless, we must take into account that
such values correspond to single-nucleotide mutations, while we are consider-
ing mutations or acquisitions in the abstract model of the cancer hallmarks.
Moreover, as indicated in [1], with small cell population sizes in the simula-
tions, large mutation rates are necessary to obtain the expected incidence of
cancer. So, we used the same default value considered in Abbott et al. [1] and
Spencer et al. [94] for the probability of acquisition of hallmarks in the mitotic
divisions. Also, Basanta et al. [11] worked with parameters, such as hallmark
mutation rate (10−5) and mutation rate increase for cells with acquired genetic
instability (i = 100), with the same default values.
For the grid size, we also used the same size of Abbot et al. [1] for most
of the experiments (125000 cell sites). The reason is that “even with modern
processor speeds, it is still not feasible to simulate a realistic number of cells
using an individual-based approach in which each cell is represented explicitly”
[1]. Moreover, as detailed in the next chapter, the emergent behavior will be
independent of the grid size, provided that we use a sufficient number of cells
to capture the emergent dynamics of the process with the interrelations of the
hallmarks [65][85].
Regarding hallmark self-growth (SG), as in Abbott et al. [1] and Basanta
et al. [11], cells can perform divisions only if they are within a predefined
spatial boundary, which represents a threshold in the concentration of growth
factor. These growth factors do no diffuse. The area is represented as an inner
cube of the grid, defined by the 95% of the inner space in each dimension, so it
represents 85.8% (0.953) of the 3D grid inner space. Beyond this area growth
signals are too faint to prompt mitosis (unless hallmark SG is ON in a cell).
Since the growth factors are present in the 95% of the inner space in each
dimension, the cells with the hallmark self-growth activated have advantage
in the most outer area of the grid environment, when the multicellular system
growth has reached the limits with growth factors. The chosen value is arbit-
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Figure 2.3: Self-Growth hallmark rule.
rary, as in the referenced works (Abbot et al. [1], Spencer et al. [94], Basanta
et al. [11]), but reasonable to show the effect of the hallmark SG in such a
stage. Changing the size of the area with growth factors would not change
the conclusions, except that the situation when the system growth reaches the
limits with growth factors would occur in a different time iteration.
Finally, in the simulation, there is not any boundary condition beyond the
grid size and that the outer area of the grid is not filled with growth factor.
That is, a cell cannot divide beyond the limits in each dimension and there are
not neighborhood connections, for example, between the cells of the left-side
limit and the right-side limit.
2.1.2 Hallmarks rules in a graphical way
As indicated in the simulation steps, frequently, cells are unable to replicate
because of some limitation, such as contact inhibition or insufficient growth
signal. Cells overcome these limitations through mutations in the different
hallmarks. The different tests considered in the simulation of the mitotic and
apoptotic behavior of the cells, taking into account the different hallmarks
acquired, are a set of rules that are applied to each of the cells of the 3D envir-
onment. Therefore, we are using the classical concept of a cellular automaton
where the rules are applied to a cell of the grid-like environment when an
event is popped from the event queue regarding that cell and site. Figures 2.3
to 2.7 show, in a schematic view, the implications of the rules of the cellular
automaton.
Figure 2.3 graphically illustrates the rule for the hallmark self-growth. As
explained, a normal cell can perform divisions only if it is within a predefined
spatial boundary area. However, if the hallmark SG is acquired (ON), the
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Figure 2.4: Ignore Growth Inhibit hallmark rule.
Figure 2.5: Evade Apoptosis hallmark rule.
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Figure 2.6: Effective Immortality hallmark rule.
Figure 2.7: Genetic Instability hallmark rule.
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cell can perform mitosis out of the predefined area with growth factor. In the
Figure an example in 2D is shown but in the simulation a 3D space is used.
In Figure 2.4 the rule of the hallmark ignore growth inhibit is explained.
A normal cell cannot perform mitosis if there is no empty space in its neigh-
borhood, unless the hallmark IGI is ON. In this last case, a neighbor is killed
probabilistically to make room for mitosis. These cells (hallmark IGI ON)
have a probability 1/g of replacing a neighbor, as indicated in Table 2.1.
Figure 2.5 explains the rule of the hallmark evade apoptosis. A cell with
the hallmark EA activated does not die by apoptosis.
Figure 2.6 illustrates the rule regarding hallmark effective immortality. A
normal cell dies when its telomere length (decreased in every cell division)
reaches the value 0, but a cell with the hallmark EI activated can continue
dividing indefinitely.
Finally, Figure 2.7 graphically explains the rule of the hallmark genetic
instability. A cell with this hallmark activated increases the hallmark mutation
rate by a factor i, as indicated in Table 2.1.
2.2 Examples of simulation runs
This section illustrates exploratory initial simulations using the event model
explained. Figure 2.8 shows the evolution over time of the number of healthy
and cancer cells for two different values of the parameter m, which defines
the hallmark mutation rate, maintaining the rest of the parameters in their
default values and using the same grid size (125000, grid with 50 sites in each
dimension) employed in [1]. The number of time iterations was 1000 in the
different runs. A cell was considered as cancerous if any of the hallmarks
was present. As expected, with increasing hallmark mutation rates (1/m),
the increase in cancer cells becomes faster. For lower values of the hallmark
mutation rate it is difficult to obtain rapid cancer progression, so we selected
those two high values.
Figure 2.8: Evolution through time iterations of the number of healthy cells
(continuous lines) and cancer cells (dashed lines) for two different hallmark
mutation rates (1/m) and default parameters. It also appears in continuous
red line the fit curve for cancer cells using a Gompertz function.
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Rodriguez-Brenes et al. [84] analyzed tumor growth patterns and they
classified them into five fundamentally different categories:
• The exponential growth is the simplest model used to describe tumor
growth. Several leukemias and lymphomas exhibited exponential growth,
most notably the L1210 leukemia [90]. Exponential growth has also been
documented to describe the growth dynamics of certain non-solid cancers
[27], but this law is not applicable to most solid tumors over long time
periods.
• The surface growth suggests a linear relation between time and the dia-
meter of a tumor. The models that follow this pattern use the basic
idea that most of the growth activity is concentrated at the boundary of
the tumor (cells near the surface divide more often than the cells in the
core).
• The Sigmoidal growth is comprised by three distinct phases: the ini-
tial exponential phase, the linear phase, and the plateau where popula-
tion size stabilizes (saturation). If the growth rate decays exponentially,
we get the Gompertz law [84]. There is empirical evidence that tumor
growth follows a Gompertz function in a lot of cancer types. In the
1960s, A.K. Laird [50], for the first time, successfully used the Gompertz
curve to fit the growth of 19 tumor lines (ten mice, eight rats, and one
rabbit) using the following equation: V (t) = [V0eA/B(1−e
Bt)] where V
represents the tumor size, in appropriate units, at any time t, V0 is the
initial tumor size, and A and B are constants that vary depending on
the type of cancer. Since then, this equation has been extensively used
in this context.
• Atypical growth corresponds to other data sets, of solid and non-solid
tumors, that do not conform to the growth laws described so far. These
data sets show sub-cubic growth for solid tumors and sub-exponential
growth for non-solid tumors.
• Multistep growth is an irregular growth pattern based on the idea that
the development of cancer is a multistep process in which cells gradually
become malignant through a progressive series of alterations (random
mutations and epigenetic changes) [62][70]. An irregular pattern of tu-
mor growth generally incorporates plateaus or dormant periods separ-
ated by Gompertzian growth periods.
In the runs of Figure 2.8, using the standard parameters, the tumor growth
follows a Gompertz curve since we have the three distinct phases: exponen-
tial phase, the linear phase and the saturation. In this figure a Gompertz
growth curve is included for comparison with respect to the growth curve of
the simulations (cancer cells). Depending on the parameters of the simulation
the different phases are more o less pronounced. The inserted curve with a
Gompertz type growth in Figure 2.8 with m=100 has the following constants
of the Gompertz function: V0=1, A=0,1845 and B=0,016. For the case of
m=1000 the constants are: V0=1, A=0,087 and B=0,00879. Nevertheless, we
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are not interested in this thesis in the tuning of the model parameters to fit a
particular cancer type, since we focus our aims on the hallmarks implications




In this chapter we study the evolution of hallmarks in different representat-
ive situations of the first phases of cancer growth, regarding initial conditions
and parameters, analyzing the relative importance of the hallmarks for tumor
progression. The presence of the cancer hallmarks defines cell states and cell
mitotic behaviors. As previously explained, these hallmarks are associated
with a series of parameters, and depending on their values and the activation
of the hallmarks in each of the cells, the system can evolve to different dynam-
ics. Such possible dynamics are analyzed here. Moreover, we study possible
behavior transitions in tumor growth dynamics when a treatment is applied in
different scenarios defined by the relative predominance of different hallmarks.
3.1 Dependence on hallmark parameters
In this section we show the capability of the simulation tool for obtaining
different dynamic behaviors. Figures 3.1, 3.2 and 3.3 (left part) show the
evolution over time of the number of healthy and cancer cells for different values
of the parameter m, which defines the hallmark mutation rate, maintaining
the rest of the parameters in their default values and using the same grid
size (125000). As in the previous initial examples in previous chapter, the
simulations began with only one healthy cell at the center of the grid. A cell
was considered cancerous if any of the hallmarks was present. The graphs are
an average of 5 different runs, given the stochastic nature of the problem. The
number of time iterations was 1000 in the different runs.
The central graphs of Figures 3.1, 3.2 and 3.3 show the time evolution of the
cells with a given hallmark and such standard parameters. With the highest
mutation rate (m = 100, Fig. 3.3), despite the rapid and initial cancer cell
progression, two hallmarks present an advantage for cancer cell proliferation:
evade apoptosis (EA) and ignore growth inhibit (IGI). The first one dominates
in the cancer cell population because, as there are many mutations in the cells,
the apoptosis mechanism eliminates many of the mutated cells, except those
that have the hallmark EA acquired, which escape that control so they prolif-
erate in the cell population. The second hallmark is necessary when the space
is full, because in this situation there are no vacant sites for cell proliferation,
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Figure 3.1: Left: Evolution through time iterations of the number of healthy
cells (continuous line) and cancer cells (dashed line) with m= 10000 and para-
meter default values. Center: Time evolution of the number of cells with a
hallmark acquired. All the graphs are an average of 5 independent runs. Right:
Example of a 2D cross-section of a final configuration at the end of the tem-
poral evolution (at t = 1000). Healthy cells are shown in bright gray whereas
the other colors correspond to different combinations of hallmarks acquired.
except for those with hallmark IGI acquired (the free space limitation can be
ignored by such cells). It should be remembered that these hallmarks, that
allow the cells to escape those limits, are acquired by the offspring, so the
daughters can continue proliferating. Using a lower hallmark mutation rate
(m = 1000, Fig. 3.2), the hallmark self-growth (SG) is initially more predom-
inant than IGI, as cells with hallmark SG acquired proliferate rapidly when
the cells have reached the limits of the area filled with growth factor. With
the lowest mutation rate (m= 10000, Fig. 3.1), the hallmark self-growth (SG)
is the most predominant since, when the cells have reached the limits with
growth factor, the cells with that mutation can proliferate rapidly in the small
area without growth factor. In this case, the hallmark evade apoptosis (EA)
is less predominant, as there are fewer mutations in cells, so the apoptosis
mechanism is less important as a limit to cell proliferation. Table 3.1 includes
statistical information of these simulation runs, with the final information of
healthy and cancer cells at the end of the simulation at t = 1000, to know
the variability involved in the different runs. We must take into account that
the variability depends on the particular iteration at which the simulation is
ended. For example, with simulations that end with the whole grid practically
full of one type of cells, the variability of the runs is logically lower (m= 10000
in Fig. 3.1).
In Figures 3.1, 3.2 and 3.3, the subfigures at the right correspond to 2D
cross-sections of final configurations at t= 1000, corresponding to a plane that
crosses the centre of the 3D grid. These 2D cross-sections give information
about the inner distribution of the cells which is useful to understand the res-
ultant behavior. The colors correspond to different combinations of hallmarks
acquired, whereas healthy cells are shown in bright gray. With the highest
mutation rate (m = 100), most of the cells have acquired all the hallmarks
(color dark blue), whereas with lower mutation rates there is a combination
of two factors: i) mutations can be acquired randomly in any cell, so there
are cells randomly located with some hallmark acquired and ii) when one cell
acquires a hallmark, such as IGI, that cell can proliferate in its immediate
surrounding (where the new cells can acquire new hallmarks in the mitotic di-
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Figure 3.2: Left: Evolution through time iterations of the number of healthy
cells (continuous line) and cancer cells (dashed line) with m= 1000 and para-
meter default values. Center: Time evolution of the number of cells with
a hallmark acquired. All the graphs are an average of 5 independent runs.
Right: Example of a 2D cross-section of a final configuration at the end of the
temporal evolution (at t = 1000).
Figure 3.3: Left: Evolution through time iterations of the number of healthy
cells (continuous line) and cancer cells (dashed line) with m = 100 and para-
meter default values. Center: Time evolution of the number of cells with
a hallmark acquired. All the graphs are an average of 5 independent runs.
Right: Example of a 2D cross-section of a final configuration at the end of the
temporal evolution (at t = 1000).
vision), so there are clusters of concentrated or localized cells with hallmarks
acquired.
These first tests serve to check the difficulty of appearance of a cancer
growth with such default parameters, requiring high values of the hallmark
mutation rate. Note that most of the m values imply fixed dynamics in terms
of complex systems, as the dynamics ends with most of the cells in healthy
or cancerous states. Note also that we finished the runs when the emergent
behavior is obtained as consequence of the first appearance of acquired hall-
marks, without explaining the next multicellular system evolution, which in
most cases ends with the cells dying after their maximum number of divisions.
To see the effect of other hallmarks, we can inspect tumor growth ap-
pearance with low hallmark mutation rates and parameters different from the
default values. Figure 3.4 is a very representative case, where we repeated
the simulations but using a parameter set that facilitates the appearance of
cancer cells, again with a grid size of 125000. We selected values as the ones
used by Abbott et al. [1] (m=100000, tl=35, e=20, i=100, g=10, a=400) for
the determination of possible mutational pathways, that is, the sequences of
appearance of hallmarks that end in tumor growth. For example, the lower
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Figure 3.4: Left: Time evolution of the number of healthy cells (continuous
line) and cancer cells (dashed line) with a parameter set which facilitates
cancer growth. Center: Time evolution of the number of cells with a hallmark
acquired. All the graphs are an average of 5 independent runs. Right: 2D
cross-section of a final configuration at the end of the temporal evolution (at
t = 5000).
value of tl implies fewer mitoses in healthy cells, and the lower value of a fa-
cilitates that more vacant sites are available for cancer cells to propagate, in
connection with the higher probability of replacing neighbors to make room
for mitosis (lower value of g). As in the previous case, Figure 3.4 corresponds
to an initialization of the grid consistent of only one healthy cell at the center.
Table 3.1: Summary of statistics regarding Figures 3.1 - 3.4
Average Standard deviation
Figs. 3.1-3.3
m=10000 Cancer cells 7315 323Healthy cells 117284 146
m=1000 Cancer cells 21570 3159Healthy cells 103414 3399
m=100 Cancer cells 116099 3729Healthy cells 8896 3728
Figure 3.4 m=100000 Cancer cells 64409 508Healthy cells 64386 490
The left part of Figure 3.4 shows the evolution of the number of healthy
and cancer cells, whereas the central part of Figure 3.4 shows the time evolu-
tion of the cells with a given hallmark and that parameter set. The dominant
hallmark in that tumor growth is effective immortality (EI), allowing the pro-
gression of the cells with that mutation even when the telomere length reaches
its limit. We must take into account that the original cell at the center of
the grid has only 35 opportunities to divide, whereas the descendants (which
acquire shortened telomeres) have even fewer mitotic opportunities. Thus, the
cells which have acquired the mutation EI have no such a limit to prolifer-
ate, which represents a clear advantage with respect to healthy (non-mutated)
cells, which die after the maximum number of 35 divisions. This explains the
rapid proliferation of the hallmark EI, before iteration 1000, when the healthy
cells have performed their maximum number of mitotic divisions.
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Figure 3.5: Snapshots of the cellular system at different time steps using the
parameter set of Figure 3.4 (Grid size=106).
When there is a high number of cells with the hallmark EI acquired, other
limits to cell proliferation begin to be important. The first limit is again the
apoptotic process when the cells have acquired more mutations. Hence, around
time iteration 2000, cells that acquired the hallmark evade apoptosis (EA) tend
to increase in number, as its acquisition represents again an advantage against
the proliferation limit. The other limit is when the cells have reached the
extremes of the area with growth factor, so cells that have acquired the hall-
mark self-growth (SG) begin to proliferate beyond the area with growth factor.
The hallmark ignore growth inhibit (IGI) does not proliferate rapidly as in the
previous case (Figure 3.3, m = 100), because now there are more vacant sites
since many cells provide free sites after their maximum number of divisions,
together with the higher value of random cell death (parameter a). The right
part of Figure 3.4 shows again a cross-section of the final configuration in one
of the runs, which shows a clear localized pattern of cells with the hallmark
EI acquired (green cells), which is clearly advantageous in that scenario. Note
that the proliferation begins in areas of the outer part of the growth, when the
healthy cells performed the maximum number of divisions. As the mutation
rate is low, in the inner part practically there are not cells with hallmarks
acquired.
Figure 3.5 shows snapshots at different time states of the multicellular
system in a run with the previous parameters, depicting the beginning of
tumor progression. The grid was initialized with only one healthy cell at the
center. In this run a grid size of 106 was used, with the aim of achieving better
visualization of tumor growth. Again, the cancer cells are shown in different
colors (depending on which hallmarks are activated) whereas the healthy cells
are depicted in dark gray. The predominant hallmark is EI in the initial cancer
cell proliferation (green cells), showing the advantage of this hallmark when
there is still free space in the grid. This is also an example that shows that the
emergent behavior is independent of the grid size, since in both cases (Figures
3.4 and 3.5) the same parameters were used, showing how the proliferation of
cancer cells with the hallmark EI acquired begins in the outer area.
3.1.1 Dependence of the emergent behavior on initial conditions
The previous examples and graphs correspond to initial situations with only
one healthy cell at the center of the grid. This is the strategy used in most sim-
ulations found in previous works. To check if the initial condition determines
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Figure 3.6: Evolution through time iterations of the number of healthy cells
(continuous lines) and cancer cells (dashed lines) using an initial grid full
of healthy cells (left), together with the evolution of the different hallmarks
(right). The upper graphs correspond to the emergent behavior with para-
meter default values and m = 100, whereas the bottom graphs correspond to
the behavior obtained with the parameters of Figure 3.4. All the graphs are
an average of 5 independent runs.
the results in terms of emergent behavior obtained, we repeated the analysis
but using an initial situation where the grid was initially full of healthy cells.
Figure 3.6 shows the emergent behaviors obtained with two of the previous
cases, using default parameters and m = 100 (Figure 3.3) and using the same
parameter set of Figure 3.4.
In all cases, the final results are the same independently of the initial
condition, except that this second and more realistic strategy needs more time
iterations to reach a stable number in both types of cells. This is because
there are fewer vacant sites in the grid to perform mitotic divisions, which
does not allow the rapid progression of the cells as in the first strategy. The
upper graphs of Figure 3.6 show the time evolution of healthy and cancer cells
with parameter default values and m = 100, together with the time evolution
of the hallmarks. This graph shows practically the same evolution of the
hallmarks with respect to the case of beginning with only one healthy cell at
the center of the grid, except the higher predominance of IGI with respect
to EA, since the grid was (practically) full from the beginning. The bottom
part of Figure 3.6 corresponds to the emergent behavior obtained with the
parameters of Figure 3.4 but using again an initially full grid of healthy cells.
For example, with this second strategy, the 100000 time iterations shown in the
graphs correspond approximately to an average time of 29.7 years taking into
account the corresponding biological time explained in the previous chapter.
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The bottom graph on the right shows only the time interval of the transition
between healthy and cancer cells, which begins after time iteration 52000, for
a better visualization of the evolution of the hallmarks. Again, the hallmarks
show the same evolution pattern of Figure 3.4, with a first predominance of
EI with respect to EA, which is progressively reduced in next iterations.
3.2 Coupling between parameters
The previous examples correspond to specific scenarios with selected para-
meters in order to show representative situations regarding the emergence of
different growth behavioral regimes and their dependence on hallmarks and
hallmark parameters. Additionally, the simulations can visualize the coupling
between parameters, that is, the resultant behavior can be inspected when
the values of two parameters are changed, maintaining the rest at fixed val-
ues. Figure 3.7 corresponds to different examples changing two parameters,
showing the final number of cancer cells after 1000 time iterations. Moreover,
these examples in Figure 3.7 help to understand the main implications of the
parameter values. In Figure 3.7.a the parameters g (which controls the hall-
mark IGI) and e (which controls the hallmark EA) were changed around their
default values while the rest of parameters were set at their default values,
except m= 1000. Figure 3.7.a shows that, when the value of g is decreased, as
expected, the number of cancer cells tends to increase given the higher prob-
ability of invasion (1/g) of the cells that acquired the hallmark ignore growth
inhibit (IGI). When the parameter e is increased, the number of cancer cells
also increases given the lower probability of cell death by the apoptotic process
(n/e, see Table 2.1). However, this effect with the parameter e is lower with
respect to the fast increase of cancer cells with a small change of the parameter
g, as it can be seen in the upper graph with the rapid increase of the number
of cancer cells with values of g around 10.
Figure 3.7.b corresponds to a sweep of the parameters i, which controls the
hallmark Genetic Instability (GI) and e, again with the rest of parameters at
their default vales and m= 1000. The increase in the orders of magnitude of i
implies a slow increase in the final number of cancer cells, since the parameter
only affects the cells that acquired the hallmark GI. As in the previous case,
the increase of the value of e implies a low increase of the number of cancer
cells, given the lower probability of apoptosis as consequence of the acquired
hallmarks. Finally, Figure 3.7.c shows the results when the parameters m and
g are changed while the rest were fixed at their default values. As remarked
before, a decrease in the value of g means that the cells with the hallmark
IGI acquired have a higher invasion potential in the surrounding tissue, as it is
shown in the bottom graph, where the fast increase in the cancer cells with low
values of g begins earlier. Nevertheless, the increase of the hallmark mutation
rate (1/m) has a greater effect on the number of final cancer cells after the
limited number of time iterations considered.




Figure 3.7: Number of final cancer cells when two parameters are changed,
while the rest of parameters are set at their default values, except m = 1000
(a and b). The z axis shows the final number of cancer cells after 1000 time
iterations in the simulation. a) Change of parameters e (which controls EA)
and g (IGI). b) the parameters e (EA) and i (GI) were changed. c) the
parameters m (hallmark mutation rate) and g (IGI) were changed. All the
graphs are an average of 5 independent runs.
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3.3 Relative importance of hallmarks
The aim in this section is to inspect the relative importance of each hallmark
in the emergent behavior of tumor growth. To answer this, we can analyze
the growth behavior when the individual hallmarks are not present or do not
imply any effect on the cellular behavior. This is the same as considering that
mutations do not activate a particular hallmark. We selected two representat-
ive cases to study the effect of not considering the individual hallmarks, that
is, to inspect the relative importance of each hallmark in the cancer growth
behavior. Note that this analysis can be very useful to establish the most ap-
propriate therapeutic targets. As pointed out by Hanahan and Weinberg [40]
“rapidly growing armamentarium of targeted therapeutics can be categorized
according to their respective effects on one or more hallmark capabilities”, al-
though, as the same authors state, “each of the core hallmark capabilities is
regulated by partially redundant signaling pathways. Consequently, a targeted
therapeutic agent inhibiting one key pathway in a tumor may not completely
shut off a hallmark capability” [40], although different drugs can act against
specific hallmarks, as indicated for example with the categorization of thera-
peutic agents attacking specific hallmarks detailed by Luo et al. [56].
First, Figure 3.8 (Left part) shows the evolution across time iterations of
the number of cancer cells (grid size=125000), using the default parameters
with m = 100, when all the hallmarks are considered (previously shown in
Figure 3.3), and when a particular hallmark is not taken into account in the
rules of apoptotic and mitotic behaviors. As seen in Figure 3.8, the most
important hallmark regarding the growth of cancer cells is evade apoptosis
(EA), since its elimination implies a high decrease in the number of cancer
cells. This is because, without the consideration of EA, all the cancer cells
have a probability of death by apoptosis, so cancer cell proliferation is highly
decreased.
The next most important hallmark is ignore growth inhibit (IGI), since its
elimination implies also an important decrease in the number of cancer cells.
This is because when the grid is almost full of healthy or cancer cells, after
time iteration 200, the main limit for the mitotic divisions is the available free
space. In this situation, the cancer cells with the hallmark IGI activated have
an advantage, as they can replace (with a given probability) a neighbor cell
to replicate. So, if this advantage does not exist when hallmark IGI is not
considered, the cancer cells tend to remain stable in number, even with this
very high hallmark mutation rate (1/m). A hallmark with similar relevance is
genetic instability (GI), as without its consideration there are fewer mutations
or acquisition of hallmarks. The previous effects are not present with the
elimination in the simulation of the other hallmarks, as it implies a smaller
decrease in the number of cancer cells.
The right part of Figure 3.8, in an alternative and similar analysis, shows
the same evolution when only one particular hallmark is considered. As the
Figure denotes, hallmarks EA and IGI are again the most relevant, and be-
cause the same reasons exposed. Note that now, when only genetic instability
(GI) is considered, the number of cancer cells with only such a mutation
cannot growth across time iterations. This is because GI only increases the
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Figure 3.8: Left: Effect of elimination of an individual hallmark. Right: Num-
ber of cancer cells when only one hallmark is considered. Simulations with
parameter default values and m = 100, averaged with 5 independent runs.
mutations in such cells for the acquisition of the other hallmarks that have
a possible effect on the proliferation of cancer cells. Note also the difference
between the hallmark relevance and the number of cells with a given hallmark
(Fig. 3.3), since the relative relevance between EA and other hallmarks is not
reflected in Figure 3.3.
Figure 3.9: Number of cancer cells when an individual hallmark is not con-
sidered (Left) and when only one hallmark is considered (Right). Simulations
with parameter values of Figure 3.4, averaged with 5 independent runs.
In Figure 3.9 we repeated the same analysis with the parameter set pre-
viously used in Fig. 3.4, which facilitates the appearance of cancer cells. As
the Figure shows, when we do not consider the hallmark effective immortality
(EI) in the simulation, the number of cancer cells is maintained to a minimum
(close to 0, dark blue line). This is because, in this case, the great advant-
age of the limitless replicative potential is never present, so all cells have the
same limit of replications imposed by the initial telomere length. The other
hallmarks do not have relevance except the low relevance of self-growth (SG),
as not considering it eliminates the final possible progression of cancer cells
in the area without growth factor. It should be noted again that the relative
relevance is not directly inferred from the evolution of the cancer hallmarks
(Figures 3.4 and 3.6).
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Table 3.2: Drugs that target specific hallmarks
Drug Hallmark targeted Comments
Bevacizumab Angiogenesis It blocks the potent angiogenic
factor VEGF (Vascular Endothelial
Growth Factor) to stop the an-
giogeneic ability of cancer.
Paclitaxel Self growth Inhibits mitosis to stop cancer cells
from dividing. Cancer cells with
self growth hallmark can divide
without growth factors but this
drug blocks their division.
GV1001 Effective immortality It is a therapeutic peptide cancer
vaccine targeting telomerase. Te-
lomerase is an attractive target an-
tigen for cancer immunotherapy be-
cause it is expressed almost uni-
versally in human cancers. This
vaccine sensitizes immune cells to
tumor cells expressing telomerase
peptides as surface antigens. This
causes an expansion of telomerase-
specific cytotoxic T lymphocytes,
directing the patient’s own immune
system to target and kill telomerase
positive tumor cells.
Imatinib Evade apoptosis It is a tyrosine-kinase inhibitor used
in the treatment of multiple can-
cers, especially leukemia. Imat-
inib blocks the BCR-ABL enzyme
in cells with an abnormality of chro-
mosome 22 and, as a result, these
cells stop growing and even die by
apoptosis.
Gendicine Evade apoptosis A drug that activates normal p53,
this is used to treat head and neck
cancers by activating normal p53
function (DNA repair, the induc-
tion of apoptosis,...) [14].
Flavopiridol Ignore growth inhibit It is an inhibitor of several cyclin-
dependent kinases (CDKs), a fam-
ily of proteins that regulate the cell
cycle. It targets over expressed cyc-
lins that allow cells to evade RB
signals (RB protein is a tumor sup-
pressor) and over-grow.
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As indicated recently by Hanahan and Weinberg [39], in addition to provid-
ing a solid basis for cancer research, the hallmarks have served to identify cer-
tain cell functions that have become therapeutic targets. However, the utility
of such attempts has been limited because tumor cells have demonstrated an
ability to develop resistance to drugs that disrupt a single pathway. This ad-
aptability of cancer cells suggests to Hanahan and Weinberg that simultaneous
targeting of two or more hallmark pathways may be a more effective approach
to therapy. So, our study indicates the importance of targeting therapies to
the genetic networks and molecular pathways that control such most relev-
ant hallmarks in each environmental and multicellular system situation. In
fact, in modern therapeutic approaches most of cancer drugs are deliberately
developed for specific molecular targets that involve the hallmarks. Following
this philosophy, in the last years drugs interfering with the hallmarks of cancer
have been developed. Some of them have already been approved, while others
are still being tested in clinical trials [9][40]. In Table 3.2 examples of drugs
that target each of the hallmarks are presented [14], whereas in Luo et al. [56]
more details are shown about therapeutics selected based on the diversity of
their chemical structures, the hallmarks they attack and their cellular targets.
Butler [14], in her PhD thesis in The University of Western Ontario (Canada),
with this work as baseline, has continued our work in this line. In her work,
hallmarks were removed in pairs, triplets and quadruplets in order to model
combination therapy, abstracting drugs that target these properties as the re-
moval of the hallmark from the system. It was found that many combinations
had no effect on tumor growth. In some cases combinations even increased
growth, selecting for the most aggressive hallmarks since weaker hallmarks
were unavailable. However, in general, as more treatments were applied, can-
cer growth decreased [14].
3.4 Analysis of behavior transitions
The aim of this section is to inspect the change in behavioral regimes between
states with predominance of one type of cells, especially when a target acts
against cancer cells. Our objective is to analyze the growth behavior trans-
itions in different circumstances. As in the previous study, the objective is
not to mimic any particular cancer type, but to show how the simulation tool
can provide knowledge to understand the implications and interrelations of the
hallmarks, in this case to analyze possible behavior transitions, and selecting
representative scenarios like in the previous sections.
Within this objective, Figure 3.10 shows a test of the decrease in cancer
cells when a possible target acts against such cancer cells, killing them. We
are supposing a perfect therapy in the sense that a drug only kills the cancer
cells. The x axis is interpreted as the probability of eliminating cancer cells
in the mitotic average time during the simulation. The mitotic events are
scheduled between 5 and 10 iterations in the future, so the average time for a
mitosis is 7.5. In practice, we applied, in each iteration or simulation time, the
killing probability shown in the x axis divided by 7.5. The y axis indicates the
number of final cancer cells. The graphs are an average of 5 different runs with
each killing probability. The only reason for this definition of the probability
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Figure 3.10: Effect of killing cancer cells during tumor growth for different
killing probabilities and using four parameter sets. The x-axis is interpreted
as the probability of eliminating cancer cells in the mitotic average time during
the simulation, whereas the y-axis represents the final number of cancer cells.
is because it is better to think in the probability of cancer cell elimination in
the average time of the mitosis (15-24 hours), being the results in terms of
behavioral transitions independent of that interpretation.
Figures 3.10.a and 3.10.b include tests using two values of the parameter
m, whereas the rest of parameters were set to their default values. In these
two cases, the Figures show the final number of cancer cells after 1000 time
iterations (y axis). As the Figures denote (Fig. 3.10.a and 3.10.b), it is easy
to maintain the number of cancer cells to a minimum. In fact, there is a
rapid decrease in the number of cancer cells (with probabilities < 0.2), which
is similar to critical phase transitions of many emergent and complex systems,
such as the Ising Model (Sole´ and Goodwin [92]), which present sudden shifts
in behavior arising from small changes in circumstances.
The third case considered in Figure 3.10.c corresponds to a scenario with
lower mutation rate (m= 10000) and different invasion potentials by ignoring
the contact inhibition mechanism, since we used different values in parameter
g. We used two values, the standard value (g = 30) and a lower value (g =
5) that confers a high invasion potential to the cells that acquire the hallmark
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ignore growth inhibit (IGI). These parameters (with g=5) used in this scen-
ario are the same used by Spencer et al. [94], in their case to study how the
sequence of acquired mutations affects the timing and cellular makeup of the
resulting tumor. Thus, cells that have acquired the hallmark IGI will have
a high capability to invade the surrounding space. Cervical cancer is an ex-
ample, whereas, on the contrary, the naked mole-rat displays hypersensitivity
to contact inhibition which confers it an extraordinary resistance to cancer
[89]. In this example, Figure 3.10.c shows again the final number of cancer
cells after 1000 time iterations (y axis). As in the first example with a high
mutation rate, there is a fast transition in the emergent behavior, again show-
ing that a small increase of the killing probability can imply a fast decrease in
the capability of cancer cells to propagate. Cells that acquired the hallmark
IGI have such a high capability, but there are few because the lower mutation
rate (with respect to the previous cases). So, the simulation shows how a little
increase in the killing probability counteracts the high invasion capability of
the few cells with IGI acquired.
Finally, we repeated the experiment using the parameter set in Figure
3.4, which facilitates the appearance of cancer cells (m=100000, tl=35, e=20,
i=100, g=10, a=400). Figure 3.10.d shows again the final number of cancer
cells after the simulation run, taking into account that the cancer cells in each
simulation iteration are eliminated with a given probability. In this case the y
axis indicates the number of final cancer cells after 3000 time iterations, since
with this parameter set more iterations are needed to overtake the rapid and
initial increase of healthy cells (as left part of Figure 3.4 denotes). With this
parameter set, the sharp behavior transition happens at a higher frequency
with respect to the previous cases, indicating the difficulty in maintaining the
cancer cells under a low threshold when the conditions make their appearance
easier. The small increase of cancer cells with low values of the killing frequency
is because, with such values, healthy cells can perform more rapidly their
limited number of mitoses (there are more available sites to complete the
maximum number of mitoses). Thus, more vacant sites are appearing for
the cancer cells with hallmark effective immortality (EI) acquired, so they
propagate more rapidly. This effect is counteracted by the increasing killing
frequency, until the final and critical behavior transition.
Nevertheless, this first strategy to inspect the behavior transitions, when
killing cancer cells, could be valid in cells cultured as monolayers, but not in
vitro three-dimensional tumor spheroids or in vivo solid tumors. As explained
by Minchinton and Tannock [64], tumors are more resistant to therapy than
cancer cells cultured as monolayers. This can be explained by “multicellular
resistance”, a mechanism for drug resistance attributed to cell-cell contacts,
cell-matrix contacts, and the three-dimensional (3D) shape found in tissue.
As Phung et al. also indicate [77] “the solid tumor microenvironment has sev-
eral major characteristics, including hypoxia, large distances between blood
vessels, high interstitial fluid pressure, structure and composition of the ex-
tracellular matrix, and cell-cell adhesion. Overall, these features of the tumor
microenvironment limit the delivery of anticancer drugs to cancer cells that
are situated far from blood vessels”. Nevertheless, as the same authors com-
ment [77], even with the simplifications of the in vitro multicellular spheroids,
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Figure 3.11: Effect of killing cancer cells during tumor growth for different
killing probabilities and using four parameter sets. The x-axis is interpreted
as the probability of eliminating cancer cells in the mitotic average time dur-
ing the simulation, whereas the y-axis represents the final number of cancer
cells. Only the most outer cells (distance of 3 or less to the boundary of the
expanding tumor) are killed with the corresponding probability indicated in
the x-axis.
these constitute a simple and relevant model of in vivo tumors “that allows for
further investigations of the microenvironmental effects on drug penetration
and tumor cell killing”.
Ma et al. [57] applied a 3D imaging method of tumor spheroids to study
the penetration behavior of doxorubicin, one of the most celebrated chemo-
therapeutics, commonly used to treat a wide range of cancers. When HeLa
cells (human cervical adenocarcinoma) were grown in a monolayer, doxorubicin
was absorbed rapidly during a short period of time. They compared the pen-
etration of doxorubicin into monolayer cells versus spheroids and found that
doxorubicin entered spheroids much more slowly than an equivalent number
of monolayer cells. As the authors state, this demonstrates that HeLa cells in
3D structures provide a multicellular resistance model that mimics the chemo-
therapy resistance often found in solid tumors in vivo.
Therefore, we repeated the analysis but considering that only the outer cells
are subject to be killed by the effect of a drug. We considered as targets the
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cancer cells in the boundary of the tumor expansion or close to the boundary,
at a Euclidean distance of 3 or less to the exterior of the expanding tumor.
We are using again a grid with 125000 sites, thus each dimension has 50 sites
or points with integer coordinates. So, the maximum distance of 3 represents,
for example, a 6% of the total distance in each dimension.
Figure 3.11 shows again the same analysis with the four parameter sets
considered before when killing all cancer cells. In the first case (Figure 3.11.a),
using the highest mutation rate (m = 100), now there is not a fast transition
in the number of cancer cells when increasing the probability of cancer cell
killing. This is because the inner cells, with many hallmarks acquired given
the high mutation rate (see cross-section of Figure 3.3), are the responsible
to renew constantly the outer area of the expansion tumor. This effect is less
clear with a lower mutation rate (m = 1000, Figure 3.11.b).
Considering the scenario of a high invasion potential, ignoring the contact
inhibition mechanism when using a lower value of the parameter g (Figure
3.11.c), the transition is quite similar to the case when all cancer cells were
killed (Fig. 3.10.c). The transition is practically as fast as in Fig. 3.10.c,
requiring a very small increase in the killing probability to practically eliminate
all the cancer cells. The reason is that there are few cells with the high invasion
potential, cells that propagate only in the outer part of the growing tumor.
So, the scenario is similar to consider the elimination of all the cancer cells.
With the higher value of the parameter (g = 30), although the lower number
of final cancer cells (with respect to g=5), the same comments can be made
with respect to the previous case in Fig. 3.10.c
On the contrary, the cases in Figure 3.11.c are different to the previous
cases with higher mutation rates, because in those previous cases (m = 100
and m= 1000, Fig. 3.11.a and 3.11.b), as indicated, a cancer cell in the inner
area can propagate rapidly if only the most outer cells are eliminated. In those
cases, the resultant vacant sites allow the easy replication of such cancer cells,
acquiring also more hallmarks given the high mutation rate.
Finally, with the parameter set used in Fig. 3.4, which uses a low mutation
rate (m= 100000) and short telomere lengths in all cells (tl= 35), there is also
a critical phase transition (Figure 3.11.d). The reason is that, in this case,
the increase in cancer cells begins in the boundary of the multi-cellular system
expansion, when a cell or cells with the hallmark effective immortality (EI)
acquired appear, so they are not limited in their number of possible replications
as the healthy cells. This expansion in only the outer area was shown in the
2D cross-section of Figure 3.4 and in the temporal progression in 3D of Figure
3.5. As in this case the inner area does not provide cancer cells, then the
transition is similar with respect to the case of killing all cells (Figure 3.10.d),
although requiring a bit higher probability of killing the outer cancer cells for
the fast transition.
Therefore, in this section, we focused on the analysis of the effect of killing
cancer cells, inspecting the time evolution of the multicellular system under
different conditions (defined by the relative prevalence of different hallmarks)
and the possible behavioral transitions between the predominance of cancer
and healthy cells. With high mutation rates and standard parameters, consid-
ering a scenario of cells cultured as monolayers, the cancer cells can be easily
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controlled supposing that a target can kill all cancer cells, with the presence
of rapid behavior transitions. When considering the growth of multicellular
spheroids, killing only the outer cells, there are not rapid transitions but a
progressive decrease of the number of cancer cells when increasing the killing
frequency. On the contrary, in situations where cells at the tumor boundary
drive tumor expansion, there are no significant differences between the consid-
eration of killing all cancer cells and killing only cancer cells at the boundary
or the tumor, such as the case considered with a high invasion potential when
ignoring the contact inhibition mechanism. Also in this case, the study showed
the difficulty in maintaining the number of cancer cells to a minimum when
the hallmark effective immortality has an advantage with respect to the rest
of the cells, and with the appearance of rapid behavior transitions between
states with predominance of both types of cells. So, this analysis represents
an alternative to the in-vitro experiments focused on the study of the compar-
ative effects of different drugs or drug combinations [22][63], since it indicates
that these in-vitro studies should also search for possible behavior transitions
when drugs are applied.

Chapter 4
Simulation of Cancer Stem
Cells
4.1 Cancer stem cell theory
A central question in cancer biology is which cells can be transformed to form
tumors. The cancer stem cell theory suggests that among all cancerous cells,
a minority of them called Cancer Stem Cells (CSC) act as stem cells that
reproduce themselves and sustain the cancer. They are responsible for the
initiation of tumor development, growth, and tumor’s ability to metastasize
and reoccur [25][34]. The transformation of a normal stem cell into a can-
cer stem cell is due to the accumulation of genetic modifications (mutations
in oncogenes, suppressor genes and miss-match repair genes) and epigenetic
alterations (abnormal methylation, histone modification) [34].
Vital studies of serial re-transplantation of harvested tumor cells into im-
munodeficient mice repeatedly reveal that large numbers of tumor cells, al-
though apparently transformed, cannot initiate new tumors [4]. Initial growth
phases are followed by remarkable decreases in tumor size up to complete re-
mission and a burden-free survival of the animal. Al-Hajj et al. [4] using a
model in which human breast cancer cells were grown in immunocompromised
mice, found that only a minority of breast cancer cells had the ability to form
new tumors. They were able to distinguish the tumorigenic (tumor initiating)
from the nontumorigenic cancer cells based on cell surface marker expression.
Cancer stem cells have been shown to have various characteristics in com-
mon with stem cells. For example, they have the capacity to divide indefin-
itely [93]. Nevertheless, to avoid speculative comparison to somatic stem cells,
alternative nomenclatures such as tumorigenic cells, tumor-initiating cells, tu-
mor rescuing units, or stem-like cancer cells are common [12]. CSCs may gen-
erate tumors through the stem cell processes of self-renewal and differentiation
into multiple cell types. So, departures from the classic view of cancer have
recently emerged [25] since, if current treatments of cancer do not properly
destroy enough CSCs, the tumor will reappear.
There are two models when considering the origin of cancer cells: The hier-
archical model assumes that tumors are originated from CSCs that give rise to
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Figure 4.1: Different models for cellular origin of cancer. Two models have been
proposed to explain the cellular heterogeneity in cancer: the stochastic model
and the hierarchical model. In the first one, every tumor cell can stochastically
generate a tumor. In the second one, only the CSCs can generate tumors.
Figure from [16], reprinted with permission from BioMed Central.
progeny with self-limited proliferative capacity where most of the cells in the
tumor are genetically homogeneous. The second model is the stochastic model
or clonal evolution model, which postulates that tumorigenesis is a multistep
process that leads to progressively genetic alterations with the transforma-
tion of healthy cells into malignant phenotypes [104]. Figure 4.1 shows the
difference between these two models.
In the hierarchical model, such CSC cells are proposed to persist in tumors
as a distinct population and cause relapse and metastasis by giving rise to
new tumors. So, different works tried to simulate their behavior, taking into
account their main characteristics, such as their capacity to divide indefin-
itely [103]. Since CSCs can cause regrowth of the tumor, it is important to
understand their behavior and effects.
4.1.1 Previous works about cancer stem cell simulation
Enderling and Hahnfeldt [25] used a hybrid mathematical-cellular automaton
model that simulated growth of a heterogeneous solid tumor comprised of
cancer stem cells and non-stem cancer cells, adopting a parameter-minimalist
approach, focused on cell proliferation, cell migration and cell death. Unlim-
ited proliferation capability, immortality and symmetric division define their
CSC modeling. While two non-stem cancer cells are always the result of non-
stem cancer cell proliferation, CSCs can divide either symmetrically to yield
two CSCs, or asymmetrically to produce a CSC and a non-stem cancer cell
(Differentiated Cancer Cell, DCC) with limited proliferation capacity. This is
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similar to the behavior of adult stem cells in their aim for maintaining and
renewing a given tissue, where the division of adult stem cells is thought to
be asymmetric. Their model showed how the introduction of cell fate het-
erogeneity paradoxically influences the tumor growth dynamic in response to
apoptosis, to reveal yet another bottleneck to tumor progression potentially
exploitable for disease control. Moreover, in [71], the authors showed that al-
though CSCs are necessary for progression, their expansion and consequently
tumor growth kinetics are surprisingly modulated by the dynamics of the non-
stem cancer cells. Their simulations revealed that slight variations in non-stem
cancer cell proliferative capacity can result in tumors with distinctly different
growth kinetics.
Vainstein et al. [98] used a 2D CA model which emphasized the distinction
between CSCs and DCCs (Differentiated Cancer cells, which do not divide and
have a limited lifespan) and assumed that CSC fate is governed by quorum
sensing, i.e., the ability of a stem cell to decide whether to differentiate, on
the basis of the number of stem cells in its neighborhood. They analyzed
how tumor progression is affected by differentiation therapy and by standard
(cytotoxic or antiproliferative) therapy, both alone and in combination. Their
simulation results showed that only treatment which simultaneously prevents
CSC proliferation and promotes differentiation can effectively eliminate CSCs
and lead to tumor eradication.
Sottoriva et al. [93] presented a mathematical model of malignancies to
investigate how a hierarchical organized cancer cell population affects the fun-
damental properties of solid malignancies. Their results indicated that tu-
mors modeled in a CSC context more faithfully resemble human malignancies
and show invasive behavior, whereas tumors without a CSC hierarchy do not.
Moreover, their results showed that the CSC model allows for significantly
higher tumor heterogeneity, which may affect therapy resistance, showing also
that therapy which fails to target the CSC population is not only unsuccessful
in curing the patient, but also promotes malignant features in the recurring
tumor.
4.1.2 Cancer stem cell modeling
For the simulation of the hierarchical CSC model we considered the scheme
that distinguishes between CSCs and Differentiated Cancer Cells (DCCs). The
CSCs have two defining properties: no limit in their proliferation capacity and
resistance to apoptosis [34]. In our model it is easy to incorporate these prop-
erties, as they imply that CSCs have acquired the hallmarks effective immor-
tality (EI) and evade apoptosis (EA). In the simulations, we will introduce a
low number of CSCs in the inner area with growth factor to check their effect
on the behavior of the multicellular system evolution.
We followed the simulation used by Enderling and Hahnfeldt [25] regarding
CSC differentiation. Thus, CSCs will divide symmetrically, with a low probab-
ility (ps = 0.01 in [25]) or asymmetrically (with probability 1−ps) to produce a
CSC and a non-stem cancer cell (Differentiated Cancer Cell - DCC). Moreover,
in our simulation, in the asymmetric division, the differentiated non-stem can-
cer cell acquires (randomly) one of the hallmarks considered in our modeling
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Figure 4.2: In the Cancer Stem Cell (CSC) model these cells can divide sym-
metrically or asymmetrically to produce Differentiated Cancer Cells (DCCs)
with limited proliferative capability.
as well as the initial telomere length which defines its finite replicative po-
tential. So, our model is more general as it considers in the CSC scheme the
different capabilities of hallmarks acquired in the cells. Thus, our model does
not consider both models about the origin of cancer cells as mutually exclus-
ive, since DCCs are genetically heterogeneous given the different hallmarks
acquired in such cells. As indicated by Yap et al. [104], there is a high degree
of convergence between the two models as shown, for example, in leukemia
[104].
Figure 4.2 summarizes the behavior of these cells. Cancer stem cells can
divide either symmetrically to yield two CSCs, or asymmetrically to produce a
CSC and a non-stem cancer cell (DCC). The probability of symmetric division
is very low, which reflects the correspondingly low fraction of cancer stem cells
reported throughout the literature. For example, as commented, Enderling
and Hahnfeldt [25] considered a probability ps = 0.01 to determine symmetric
CSC division.
Finally, a CSC can only divide when it has available space in its immediate
neighborhood. This is the same condition considered by Morton et al. [71] or
Vainstein et al. [98]. For example, Morton et al. [71] stated that “the prob-
ability of symmetric and asymmetric CSC division is constant and stochastic,
and cells require adjacent available space to migrate or proliferate”. Similarly,
in Vainstein et al. [98] the authors assumed that each CSC is either “non-
cycling” (quiescent) or “cycling”, i.e., the cell progresses through the cell cycle
and after a fixed time period divides into two CSCs. Their non-cycling CSCs
can enter the cell cycle at any time and it depends on the total cell density
in the CSC’s vicinity: the more vacant (i.e., unoccupied by other cells) space
available, the greater the probability that the CSC will enter the cell cycle.
Nevertheless, we did not use their model of a “quorum sensing” control mech-
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anism (direct stimulation of differentiation of a stem cell by its neighboring
stem cells), as we used the commented model of CSC differentiation taking
into account a probability of symmetric and asymmetric division, as in [25]
and [93].
Figure 4.3: Upper graph: Evolution through time iterations of the number of
healthy cells (continuous line), non-stem or differentiated cancer cells (DCCs,
dashed line) and Cancer Stem Cells (CSCs) (pointed line). CSCs are intro-
duced at time iteration 100 (1% of the grid size) in the grid initially full of
healthy cells. Standard hallmark parameters were used except g=5. At time
iteration t = 6000 the 100% of DCCs is killed. Bottom graph: Evolution
through time iterations of the different hallmarks in the cancer cells.
4.2 Cancer stem cells simulation
In the previous chapter we have analyzed the capabilities of the hallmarks,
with their main interrelations with other hallmarks, to promote tumor growth.
These previous analyses serve us to test now their capabilities in a cancer stem
cell context.
In their work, Enderling and Hahnfeldt [25] considered a probability ps to
determine symmetric CSC division. As the authors indicate [25], in a model
based on cancer stem cells hypothesis, only a minority of cells are presumed
to be CSCs, the rest being non-stem cancer cells with a finite proliferation ca-
pacity (maximum number of mitoses). The authors assumed that cancer stem
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cells divide symmetrically with probability ps = 0.01, reflecting the correspond-
ingly low fraction of cancer stem cells reported throughout the literature.
Our simulated CSCs will have always the hallmark effective immortality
acquired, so they will have no limit in their proliferation capacity, in addition
to the resistance to apoptosis [34]. The CSCs will divide symmetrically, with
the same probability used in [25] (ps = 0.01) or asymmetrically to produce a
CSC and a non-stem cancer cell and with probability 1− ps. As explained,
in the asymmetric division, the differentiated non-stem cancer cell acquires
(randomly) one of the 5 hallmarks considered in the simulation as well as the
initial telomere length which defines its finite replicative potential (unless it
acquires the hallmark EI). Note that this is different to the general symmetric
division that copies all the genetic information to the daughter cell. When
those non-stem cancer cells divide later, the resultant non-stem cancer cells
can acquire more mutations or hallmarks.
For the simulation we introduce a number of CSCs in the growth area
of the multicellular system evolution. Figure 4.3 includes a representative
example with a run of the system evolution with this simulation. The Figure
shows the evolution through time iterations of healthy cells, non-stem cancer
cells (DCCs) and CSCs, when a number of CSCs corresponding to a 1% of
the grid size (125000) was introduced at iteration 100 (1250 CSCs) in the
inner area with growth factor, with the grid initially full of healthy cells.
These incorporated CSCs are not subject to apoptosis [34], so their presence is
maintained according to the cancer stem cell theory. The value of parameter g
was set to 5 and the rest of the hallmark parameters were set to their standard
values in the run.
Since there is not practically any free site, in this situation, most CSCs
remain quiescent until they have free space to perform mitoses. Additionally,
as the probability of symmetric division is very low, the number of CSCs
remains stable during the 9000 iterations shown in Figure 4.3. However, the
non-stem cancer cells begin to grow due to the asymmetric division of the CSCs
and thanks to the acquisition of the hallmark ignore growth inhibit (IGI) in
many of such non-stem cancer cells, which can proliferate in this situation
with practically no free sites and until they reach the maximum number of
divisions (tl = 50). The value of g used in the simulation example (g = 5)
allows such a rapid proliferation thanks to their high capability to propagate in
the surrounding tissue. As more mutations are appearing in this proliferation
of non-stem cancer cells, then hallmark evade apoptosis (EA) also appears in
many non-stem cancer cells to avoid the apoptotic process.
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t= 1500 t= 2500 t= 3500
t= 5500 t= 6000 t= 6250
t= 6500 t= 7000 t= 8500
Figure 4.4: Snapshots of 2D central sections of the multicellular system evol-
ution corresponding to different time iterations in Figure 4.3 (Colors: Gray -
healthy cells, Blue - DCCs, Red-enlarged size - CSCs).
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Figure 4.4 shows cross-sections of this multicellular system evolution at
different time iterations. These cross-sections correspond to 2D sections of
a plane that crosses the center of the grid. These 2D cross-sections show the
progressive expansion of the tumor cells (DCCs), with the colonization of many
areas previously initialized with some DCCs and thanks to the continuous
presence of CSCs (shown with enlarged sizes in the cross-sections).
CSCs have been suggested to be more resistant to therapeutic interven-
tions such as chemotherapy or irradiation compared with their differentiated
counterparts [93]. In fact, CSCs are relatively resistant to such standard cyto-
toxic and irradiation therapies since, for example, cytotoxic therapies affect
rapidly proliferating cells, whereas evidence suggests that only a small frac-
tion of CSCs actively proliferate. Hence, at time iteration 6000 the 100% of
non-stem cancer cells is killed, simulating a cancer therapy, causing the drastic
drop of the non-stem cancer cells. The healthy cells that have not performed
the maximum number of divisions fill rapidly the space (see the cross-section
at t=6250), but the non-stem cancer cells recover quickly because the CSCs
not killed produce again non-stem cancer cells, repeating a similar evolution
pattern like the one at the beginning of the simulation. Nevertheless, note that
this second proliferation on non-stem cancer cells is faster. This is because,
after killing the DCCs, there is one important detail to take into account: The
CSCs had more opportunities to differentiate in the small amount of time until
the grid is completely filled with mostly healthy cells. So, the few non-stem
cancer cells, after the differentiation, can produce the faster proliferation of
cancer cells. The fluctuations in the expansion of these cells (and consequently
in healthy cells) are because the cells with IGI acquired proliferate faster when
they are surrounded by healthy cells. However, when the concentrations or
clusters of cells with IGI acquired reach a certain size, then the apoptotic pro-
cess can decrease their size for a small time, until reaching another lower size
where the proliferation continues again.
We repeated the same analysis with another conditions. In Figure 4.5
we introduced again the same number of CSCs at t = 100 in the inner area
of the grid with the same size (125000), being this initially full of healthy
cells. In this case, all the parameters were set to their standard values except
a higher mutation rate (m = 1000). Figure 4.6 shows cross-sections of the
multicellular system evolution at different time iterations. Now, given the
higher mutation probability, the hallmark evade apoptosis (EA) becomes the
most predominant to avoid the apoptotic process. Its combination with ignore
growth inhibit (IGI) allows the cells with both hallmarks acquired to begin
to proliferate after many iterations (around time iteration 3900). These two
hallmarks are co-acquired since they are necessary to overcome two different
barriers to cancer growth: EA is necessary to avoid the barrier of the apoptotic
process, given the high mutation rate, whereas IGI is necessary to escape the
second barrier to cancer cell proliferation, since practically there is no free
space.
The growth begins in most cases near the boundary of the grid, because
cells that acquire the hallmark self-growth (SG) find an immediate advantage
in the area without growth factor (most outer area of the grid). As in the
previous case, at t= 6000, the non-stem cancer cells are killed. After that, the
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Figure 4.5: Upper graph: Evolution through time iterations of the number of
healthy cells (continuous line), non-stem or differentiated cancer cells (DCCs,
dashed line) and Cancer Stem Cells (CSCs) (pointed line). CSCs are intro-
duced at time iteration 100 (1% of the grid size) in the grid initially full of
healthy cells. Standard hallmark parameters were used except m=1000. At
t=6000 the 100% of DCCs is killed. Bottom graph: Evolution through time
iterations of the different hallmarks in the cancer cells.
same proliferation pattern happens but with a clear faster evolution, and for
the same reason as in the previous case: The CSCs had the opportunity to
differentiate just after killing the DCCs, thanks to the free sites that suddenly
appear, although these are rapidly filled mostly with healthy cells (e.g., see
cross-section at t=6100). Nevertheless, the few DCCs after the differentiation
are sufficient to cause that rapid increase of cancer cells.
Note that even we had modeled the killing of only the cancer cells that are
close to the boundary of the tumor expansion in the same sense considered in
previous chapter, the conclusion would have been the same, being this that
some CSCs (near the boundary) would have the opportunity to differentiate
in non-stem cancer cells that can renew a tumor proliferation in advantageous
scenarios, although needing more iterations. This second example (Figures 4.5
and 4.6) is also closer to this consideration, since most of the cancer cells are
close to the boundary, as the cross-sections of Figure 4.6 show.
Since the application of a standard treatment in a cancer stem context has
consequences on the tumor regrowth behavior, we can analyze in more detail
different strategies to apply a standard treatment, with the aim of minimizing
the effects of possible regrowth. This is the aim of the next chapter.
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t= 4500 t= 5000 t= 5500
t= 6000 t= 6100 t= 6500
t= 7000 t= 8000 t= 9000
Figure 4.6: Snapshots of 2D central sections of the multicellular system evol-
ution corresponding to different time iterations in Figure 4.5 (Colors: Gray -
healthy cells, Blue - DCCs, Red-enlarged size - CSCs).
Chapter 5
Treatment strategies analysis
in a cancer stem context
Designing successful cancer drugs is very challenging but equally challenging
is the design of optimal treatment scheduling. Biologists, clinicians, mathem-
aticians, computational scientists and engineers are working towards the goal
of improving the treatment scheduling. As McGuire et al. [61] mentioned:
“Researchers with different scientific backgrounds explored the topic of how to
advance metronomic drug therapy for cancer from its experimental successes
to general clinical acceptance for specific pathologies.”
In this chapter the effect of cancer treatments in a cancer stem cell context
is analyzed. The simulations can help to suggest which treatment strategies are
better taking into account the regrowth capacity of cancer stem cells considered
in the previous chapter. Most of the results considered here are described in
our works [69][87].
There is no single treatment for cancer. Doctors use different treatments,
or a combination of them, to achieve the best result depending on the concrete
case. There are three major types of treatments:
• Surgery.
• Radiotherapy: uses high-energy rays to cure or control cancer. The
high-energy radiation used during radiotherapy permanently damages
the DNA of cancer cells, causing them to die.
• Drug therapies: this therapy can be divided in two subclasses:
– Chemotherapy: uses cytotoxic drugs to kill cancer cells. There are
many types of chemotherapy drugs that can be given individually
or in combination. Usually, the drugs work by damaging the RNA
or DNA that tells the cell how to copy itself in division. If the cells
are unable to divide, they die. As with radiotherapy, the faster the
cells are dividing, the more likely it is that drugs will kill the cells.
In other words, chemotherapy destroys healthy and cancerous cells
in the proliferative state but is most effective at killing cancer cells
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because these have higher proliferative fractions than normal cells.
This type of chemotherapy drugs are called cell-cycle specific (an-
timetabolites, vinca alkaloids, taxanes, epipodophyllotoxins, camp-
tothecans), while other drugs that affect cells when they are at rest
are called cell-cycle non-specific (antitumour antibiotics, Alkylating
agents, Nitrosoureas). The scheduling of chemotherapy is set based
on the type of cells, rate at which they divide, and the time at which
a given drug is likely to be effective. This is why chemotherapy is
typically given in cycles.
– Biological therapies: use substances that occur naturally in the
body to destroy cancer cells. The main types of biological therapies
are: monoclonal antibodies, cancer growth inhibitors, angiogenesis
inhibitors, gene therapy, vaccines and interferon (a group of signal-
ing proteins made and secreted by cells of the immune system in
response to the presence of pathogens, such as viruses, bacteria, or
tumor cells).
5.1 Previous works on cancer treatment simulation
The goal of standard therapies like chemotherapy and radiotherapy is to des-
troy the tumor cells, while maintaining adequate amounts of healthy tissue.
Optimality in treatment might be defined in a variety of ways. Some studies
have been carried out in which the total amount of drug administered, or the
number of tumor cells, is minimized. For example, in the models considered
in [96][97], the goal was to maximize the number of cancer cells killed by a
chemotherapy agent, or to minimize the number of cancer cells at the end of
the therapy session, while keeping the toxicity of the normal tissues acceptable.
In chemotherapy, the administration of one or more drugs is aimed to kill
tumor cells in which the growth rate is faster than normal cells. Within this
context, the mathematical modeling of anticancer chemotherapy has existed
for more than four decades [23][95]. For example, the Norton-Simon model
[74][91] states that the rate of cancer cell death in response to treatment is
directly proportional to the tumor growth rate at the time of treatment. This
model, for cell-cycle specific drugs, suggests that moderate early doses followed
by later dose intensification would kill more tumor cells [74].
In the work of De Pillis and Radunskaya [20], the authors attempted to find
equilibrium for a chemotherapy administration schedule that would kill off the
tumor cells as effectively as possible, with the constraint that the treatment
must not kill too many normal cells. Their optimal control algorithm dictates
that a drug must be administered continuously over relatively long periods of
time (on the order of days). Other authors have also applied techniques from
optimal control theory to discover how chemotherapy and immunotherapy can
best be combined for the effective treatment of cancer [47].
Several models predict that continuous infusion (in particular of cell-cycle
phase specific drugs) is more effective than short pulses [53]. However, if the
drug is applied too slowly by continuous infusion, drug resistance may develop
[53]. Gardner [28] modeled this trade-off considering cell-cycle specific and
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cell-cycle nonspecific drugs, and used his model to provide insight into how
the chance of a cure is connected with the dose and type of infusion.
These representative examples are not an exhaustive list of the works re-
lated to in silico studies about treatments. This present study is related to




In the simulations the effect of a cancer treatment taking into account the
presence of CSCs is simulated. Generic cancer protocols in early avascular
stages of cancer are considered, given that they are ideal treatments that
only kill the cancer cells, although this simplification does not change the
conclusions to be drawn here. For this study representative scenarios have
been considered in order to analyze the behavior of the multicellular growth
when a treatment is applied.
A grid of 125000 cell sites, as in [1] and [94], was considered again. For
the simulation a number of CSCs in the inner area with growth factor (in
random positions) was introduced at the beginning. The simulations begin
with the grid full of cells all of which are healthy except the incorporated
CSCs. Nevertheless, the emergent growth behaviors are independent of this
initial condition (the initial number of healthy cells) as well as the grid size,
as indicated in chapter 3.
As explained in chapter 4, CSCs will divide symmetrically, with the same
probability used by Enderling and Hahnfeldt [25] (ps = 0.01), or asymmet-
rically to produce a CSC and a non-stem cancer cell with probability 1−ps.
Regarding the number of CSCs introduced from the beginning, this corres-
ponds to a small percentage of the grid size (1-5%) since the proportion of
identified CSCs varies among different cancers. For example, Ricci-Vitiani
et al. [83] showed that tumorigenic cells in colon cancer population (with
CD133+ marker) accounts for about 2.5% of the tumor cells and Korkaya et
al. [49] determined that CSCs comprise 1-5% of primary tumors in human
mammary carcinomas.
5.2.2 Effect of treatments on regrowth behavior
In order to explain the effect of treatments in a CSC context, a scenario with
high invasion potential where the value of parameter g was set to 5 and the
rest of the hallmark parameters were set to their standard values in the runs
was considered again. Nevertheless, the explanations and conclusions would
be similar in other scenarios. This therefore corresponds to a scenario with
a high invasion potential by ignoring the contact inhibition mechanism (with
probability 1/g), since such a low value in parameter g (5) was used. Thus,
cells that have acquired the hallmark ignore growth inhibit (IGI) will have a
high ability to invade the surrounding space.
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Figure 5.1: Tumor regrowth after a high-intensity treatment. The graph shows
the evolution through time iterations of the number of Differentiated Cancer
Cells - DCCs (continuous red line) with g=5 while the rest of the parameters
were set to their standard values. A number of Cancer Stem Cells (CSCs)
corresponding to 1% of the grid size is introduced from the beginning of the
simulation (dashed green line). At iteration 5000 the 100% of DCCs is killed.
The graph also shows the evolution of the two most predominant hallmarks
acquired in cancer cells (IGI and EA). The bottom part shows snapshots of
central sections of the multicellular system evolution corresponding to different
time iterations (Colors: Gray - healthy cells, Blue - DCCs, Red-enlarged size
- CSCs).
Fig. 5.1 includes an example of this scenario with a run of the system
evolution, which is similar to the one previously used in the previous chapter.
The upper part of Fig. 5.1 shows the evolution through time iterations of non-
stem cancer cells (DCCs) and CSCs when the number of CSCs corresponds to
1% of the grid size (125000), CSCs that were introduced at the beginning in
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random positions of the inner area with growth factor. As explained, the grid
is initially full of cells which are practically all healthy except for the CSCs
incorporated. Fig. 5.1 also shows the evolution of the two most predominant
hallmarks (considering the hallmarks acquired in all cancer cells) during the
multicellular system evolution.
Figure 5.2: Evolution through time iterations of the number of DCCs with
the same setup of Fig. 5.1 and including CSC differentiation. At t = 5000 a
standard treatment is applied, killing the 100% of DCCs. After that, a CSC
differentiation treatment is applied, with three different percentages of CSCs
differentiated.
Since there is not practically any free site, most CSCs remain quiescent
until they have free space to perform mitoses. Given the low probability of
symmetric division the number of CSCs remains stable during the 6000 iter-
ations shown in Fig. 5.1. However, as explained in the previous chapter, the
non-stem cancer cells begin to grow due to the asymmetric division of CSCs
and because of the acquisition of the hallmark ignore growth inhibit (IGI) in
few of the DCCs, which can rapidly proliferate because of their advantage in
this situation with practically no free sites (the daughters acquire the same
hallmark). As more mutations appear in this proliferation of DCCs, the apop-
totic process begins to be an important limit for their proliferation. Therefore,
as an evolutionary and emergent consequence, the hallmark evade apoptosis
(EA) also appears in many DCCs to avoid the apoptotic process.
At time iteration 5000 the 100% of non-stem cancer cells is killed, simulat-
ing a (perfect) cancer therapy and causing the drastic drop of the non-stem
cancer cells. Nevertheless, as explained in previous chapter, since CSCs are
more resistant to therapeutic interventions, such as chemotherapy or irradi-
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ation, compared with their differentiated counterparts [93], the CSCs remain
in the simulation.
The bottom part of Fig. 5.1 shows cross-sections of this multicellular sys-
tem evolution at different time iterations. The snapshot at t= 5000 shows how
these DCCs are eliminated by the effect of treatment. The next snapshots show
how the healthy cells that have not performed the maximum number of divi-
sions fill the space rapidly (see for example the cross-sections at t=5020 and
5250), but the non-stem cancer cells recover quickly because, as also explained
in the previous chapter, the CSCs not killed produce non-stem cancer cells
again. These DCCs produce an evolution pattern similar to the one at the
beginning of the simulation, as shown in the cross-sections and in the upper
part of Fig. 5.1.
Vainstein et al. [98] considered the stimulation of CSC differentiation. A
“differentiation therapy” (like retinoic acids and drugs targeting tumor epigen-
etic changes) force CSCs to differentiate terminally and lose their self-renewal
property [38]. Therefore, Vainstein et al. [98] proposed that, in clinical tri-
als, CSC differentiation therapy should only be examined in combination with
chemotherapy to substantially reduce the population sizes and densities of all
types of cancer cells. We considered also this possibility, so, after the standard
treatment against DCCs, a percentage of CSCs is differentiated. Figure 5.2
includes a comparison of DCC evolution using the previous scenario (g = 5
and default values in the rest of parameters) and differentiation therapy. This
means that CSCs are transformed to DCCs, acquiring randomly one of the
5 hallmarks, so the number of CSCs is decreased and the number of DCCs
is increased. We have considered three different percentages of CSC differ-
entiation, where we simulated the differentiation in only one iteration, which
does not affect the conclusions. When CSCs are differentiated, the slope of
the DCC increase is a bit higher with respect to the case of no differentiation,
as it is logical since more DCCs (some with the hallmark IGI acquired) are
immediately present to begin the fast proliferation. However, in the long term,
with fewer CSCs the number of DCCs is best controlled (note that the other
limits for DCC proliferation are active, like the apoptotic process).
The experiment was repeated but this time by considering a situation where
the treatment kills DCCs gradually and within a given period. Fig. 5.3 shows
another run although now the treatment is applied between iterations 5000
and 6000, killing 1% of DCCs in each iteration. Now there is an important
difference after the beginning of the treatment, because in the next iterations
the healthy cells rapidly replace the free sites that are appearing as a con-
sequence of the elimination of a limited number of DCCs. Most of the few
CSCs are therefore immediately surrounded by cells, without the possibility of
proliferation and differentiation as in the previous case. This can be observed
in the snapshots corresponding to iterations 5000 and 5250.
At time iteration t = 6000 the treatment is ceased and DCCs begin to
proliferate again. Nevertheless, the slope in the regrowth is not as high as in
the previous case (Fig. 5.1) because the treatment strategy did not allow the
differentiation of a significant number of CSCs as in that first case. This can
be seen in the evolution graphs (Fig. 5.1 and Fig. 5.3) or in the snapshots. For
example, the comparison of the snapshot of Fig. 5.1 at t= 6000 (1000 iterations
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Figure 5.3: Tumor regrowth after a low-intensity treatment. The graph shows
the evolution through time iterations of the number of Differentiated Cancer
Cells - DCCs (continuous red line) with g=5 while the rest of the parameters
were set to their standard values. A number of Cancer Stem Cells (CSCs)
corresponding to 1% of the grid size is introduced from the beginning of the
simulation (dashed green line). Between iterations 5000 and 6000 DCCs are
killed with a probability of 1% in each iteration. The graph also includes the
cases when, in the same interval, a CSC differentiation treatment is applied,
differentiating 0.01% and 0.1% of CSCs in each iteration. The bottom part
shows snapshots of central sections of the multicellular system evolution at
three different time iterations corresponding to the first case (no differentiation
therapy) (Colors: Gray - healthy cells, Blue - DCCs, Red-enlarged size - CSCs).
after the beginning of the regrowth) and the snapshot at t = 8000 of Fig. 5.3
(2000 iterations after the beginning of the regrowth since the treatment ceases
at t = 6000), clearly shows the faster increase of DCCs using a high intensity
treatment in a short period. This therefore indicates and explains that this
strategy, the application of a treatment against non-stem cancer cells with low
intensity and with a longer period, is better regarding the future regrowth of
the tumor behavior. It should be noted that this conclusion is a consequence of
the higher probability of CSCs proliferating and differentiating which is favored
with treatments with high intensity. Moreover, this effect is independent of the
particular advantage of DCCs proliferating, although in this example such a
scenario, where cells with the hallmark IGI acquired are the most predominant,
was chosen.
We also included the cases in which very low intensity CSC differentiation
treatments are applied in the same interval (t = 5000 - t = 6000). With a
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treatment that differentiates 0.01% of CSCs in each time iteration, practically
there is not any difference with respect to not using a differentiation ther-
apy since the key aspect is to block CSC proliferation. Meanwhile, using a
treatment that differentiates 0.1% of CSCs in each time iteration, no CSCs re-
main at t = 6000 which could contribute to the continuous increase of DCCs.
Moreover, in order to have effective treatments, the relative timing of the two
treatment strategies is important, since the standard treatment must decrease
the new DCCs generated by the CSC differentiation therapy.
5.2.3 Treatment scheduling
The objective of this part of the study is to analyze treatment scheduling in
a CSC context by taking into account the effects of treatment intensity and
application period in future tumor regrowth. Two representative scenarios
were considered: the one previously used where the predominant hallmark is
ignore growth inhibit, and another scenario dominated by the hallmark evasion
of apoptosis when using an increased mutation rate.
Fig. 5.4 shows a multicellular system evolution with the same hallmark
parameters used in Fig. 5.1; that is, using a high invasion potential scenario
in which the parameter g was set to 5 and the rest of the hallmark parameters
were set to their standard values. The number of incorporated CSCs is 5% of
the grid size, a larger number with respect to previous cases to show better
CSC implications. A treatment is started from the beginning, and considering
the four cases shown in Fig. 5.4. In all cases the treatment is applied using
a simple control: it is administered unless the number of DCCs is under a
threshold value corresponding to 1% of the grid size. We use this so we can
infer conclusions about tumor regrowth without considering the extreme case
where the number of DCCs is reduced to zero, as in previous explanatory
examples.
In the first case (Fig. 5.4.a) the treatment kills 1% of DCCs in each itera-
tion. In the second case (Fig. 5.4.b) the treatment kills 10% of DCCs in each
iteration, maintaining the treatment during 60 iterations (6.5 days) and re-
peating the strategy periodically every 100 iterations (10.8 days). In the third
case (Fig. 5.4.c) the treatment is applied every 100 time iterations although
now 50% of DCCs in such iterations are killed. The fourth case (Fig. 5.4.d) is
similar although 75% of DCCs are killed when the treatment is applied every
100 time iterations. The bottom subfigures in the four cases show the number
of CSC asymmetric divisions in every simulation iteration.
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Figure 5.4: Different treatment strategies in a high invasion potential scenario.
The graphs show the evolution of the number of DCCs (continuous red line)
with g=5 (standard values in other parameters). A number of CSCs corres-
ponding to 5% of the grid size is introduced from the beginning (not shown).
The treatment is applied from the beginning only if the number of DCCs is
equal or over a threshold value (1% of the grid size). a) Treatment applied
continuously, killing 1% of DCCs. b) Treatment applied every 100 time iter-
ations, continuously killing 10% of DCCs during 60 iterations. c) Treatment
applied every 100 time iterations, killing 50% of DCCs. d) Treatment applied
every 100 time iterations, killing 75% of DCCs. The bottom parts show the
number of asymmetric divisions in CSCs.
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In the first strategy (Fig. 5.4.a), the simple adaptive mechanism of treat-
ment application maintains very close the number of DCCs to the threshold
value, with very few CSC asymmetric divisions. The number of DCCs oc-
casionally presents small increases and oscillations. The fluctuations in the
expansion of DCCs are now because some cancer cells have acquired the hall-
mark self-growth (SG) in the outer part of the grid. In this area there is not
growth factor, so empty sites appear quickly since only cells with SG acquired
can perform mitosis. When a DCC with SG acquired appears in the outer
area, a fast increase of DCCs occurs which is not controlled with the treat-
ment. When these DCCs have colonized the outer area, other factors reduce
their number, being the main reason that some cells have also acquired the
hallmark ignore growth inhibit (IGI), given that rapid proliferation. Therefore
the same reason for the oscillations in the number of DCCs in previous Figures
appears again.
In the third case (Fig. 5.4.c), after 50% of DCCs have been killed, these
recover again owing to the fast proliferation of the remaining DCCs and to the
CSC proliferation and differentiation which is now favored by the fast DCC
elimination. This last contribution has a higher importance when the number
of remaining DCCs is lower. The run also indicates that it is not necessary to
kill 100% of DCCs in order to show the fast increase of DCCs as a consequence
of the greater CSC differentiation possibility. The fourth case is similar (Fig.
5.4.d), when the treatment kills 75% of DCCs in particular iterations, although
in this case the treatment is applied fewer times with respect to the third case,
since the threshold is reached in less occasions. As in the previous case, killing
a considerable number of DCCs favors CSC differentiation, therefore DCCs
recover again to obtain a larger number of DCCs. The second case (Fig.
5.4.b) is a mixture of both strategies, as it uses a lower intensity with respect
to the last cases but it is maintained during a certain number of iterations.
It should be noted that after time iteration 5000, and since most DCCs are
located in the outer area (cells with hallmark self-growth), when the treatment
is applied it kills cells mostly in this area. The empty cells are therefore
mostly located in that area and, consequently, only the few CSCs located
there can perform the asymmetric divisions. This explains why there is a
lower number of asymmetric divisions after time iteration 5000. This effect is
clearer when many DCCs are killed, as when the treatment is applied every
100 time iterations killing 75% of DCCs (Fig. 5.4.d) and when the treatment
is applied every 100 time iterations, continuously killing 10% of DCCs during
60 iterations (Fig. 5.4.b), whereas the effect is less clear when it is applied
every 100 time iterations killing 50% of DCCs (Fig. 5.4.c).
The experiment was repeated with standard parameters and a higher hall-
mark mutation rate (m = 1000) with respect to the standard value (m =
100000). The parameter m sets the time scale of the simulation as it determ-
ines how fast tumor growth behavior can appear, although the onset of tumor
growth depends on the parameter values of other hallmarks. As previously
explained, given the increased hallmark mutation rate, the hallmark evade
apoptosis (EA) is the most predominant in DCCs in evading the apoptotic
process. Fig. 5.5 shows the same cases considered in the previous example,
except that in this case the treatment continuously applied (Fig. 5.5.a) kills
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5% of DCCs in each iteration. This higher killing frequency (with respect to
the previous example) is because it is necessary to decrease the number of
DCCs faster given the higher hallmark mutation rate. In all cases the number
of incorporated CSCs is again 5% of the grid size. The cases considered in Fig.
5.5 show once more that the same conclusions can be inferred, given that with
discontinuous treatments more number of asymmetric divisions are obtained,
whereas with continuous treatment, such a number of asymmetric divisions
is near zero and consequently fast regrowth of DCCs is not favored. This is
also the case with a low intensity treatment maintained during an appropriate
period (Fig.5.5.b) in order to decrease the number of DCCs at the same time
that low intensity does not favor the proliferation and differentiation of CSCs.
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Figure 5.5: Different treatment strategies in a high hallmark mutation scen-
ario. The graphs show the evolution of the number of DCCs (continuous red
line) with m=1000 (standard values in other parameters). Same setup as in
Fig. 5.4: a number of CSCs corresponding to 5% of the grid size is introduced
from the beginning. A treatment is applied from the beginning only if the
number of DCCs is equal or over a threshold value (1% of the grid size). a)
Treatment applied continuously, killing 5% of DCCs. b) Treatment applied
every 100 time iterations, continuously killing 10% of DCCs during 60 itera-
tions. c) Treatment applied every 100 time iterations, killing 50% of DCCs.
d) Treatment applied every 100 time iterations, killing 75% of DCCs.
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5.3 Discussion
Different strategies when a treatment is applied were analyzed by taking into
account the implications of CSC presence. These cells are resistant to usual
present therapies, so these are the main cause responsible for tumor regrowth
after treatments. As stated by Sottoriva et al. [93] “Therapy which fails to
target the CSC population is not only unsuccessful in curing the patient, but
also promotes malignant features in the recurring tumor. These include rapid
expansion, increased invasion, and enhanced heterogeneity”. This present ana-
lysis is therefore different to the studies focused on treatment applications to
control non-stem cancer cells, given that its aims center upon future tumor
regrowth in the long term as a consequence of the CSC behavior.
Vainstein et al. [98] employed a CSC simulation that takes into account a
quorum sensing model (higher CSC density in the microenvironment promotes
CSC differentiation). Their model considers “cycling CSCs” which are those
CSCs that progress through the cell cycle and after a fixed time period divide
into two CSCs, whereas the “non-cycling” CSCs are the quiescent CSCs that
enter the cell cycle depending on the total cell density in the CSC’s vicinity.
Even the authors remark that their model’s assumptions differ from those of
other models of CSC dynamics, which either do not consider differentiation as
a process triggered by environmental feedback or do not take into account the
influence of neighboring cells on the differentiation decision (such as the model
of Enderling and Hahnfeldt [25] and our study’s model), they also showed that
“accelerated death of DCCs (represented in their model by limited lifespan)
decreased the number of DCCs, but increased the number of cycling CSCs”.
Although using a different model of CSC differentiation, this aspect of their
model is similar to the results of our study regarding the relation between DCC
elimination and CSC differentiation. Moreover, those authors [98] stated that
neither stimulation of CSC differentiation or inhibition of CSC proliferation
alone is sufficient for complete CSC elimination and cancer cure, since each of
these two therapies affects a different subpopulation of CSCs.
Our results concerning the faster regrowth after a treatment are also in
agreement with the results of Hillen et al. [42] when they comment regarding
“tumor growth paradox”. The authors define this paradox as an “accelerated
tumor growth with increased cell death as, for example, can result from the
immune response or from cytotoxic treatments”. They showed that if DCCs
compete with CSCs for space and resources, the first cells can prevent CSC
division and drive tumors into dormancy. Conversely, if this competition is
reduced by death of DCCs, as the authors state “the result is a liberation
of CSCs and their renewed proliferation, which ultimately results in larger
tumor growth”. Their model only considers DCCs with limited proliferation
capability, whereas the model employed in our study considers the different
hallmarks that a DCC can acquire; therefore the different capabilities of the
individual hallmarks can be analyzed in different situations. Nevertheless, the
conclusions drawn here are the same in different scenarios characterized by
the relative importance of the different hallmarks and clearly indicate that the
treatments applied must not promote CSC division.
Finally, the effects of different treatment strategies were analyzed by using
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continuous low-intensity treatments and periodic high-intensity treatments.
The former presents an advantage as a continuous low-intensity treatment
which does not favor CSC proliferation and differentiation, and therefore al-
lows easy control of future tumor regrowth. On the contrary, the latter pos-
sibility of discontinuous periodic treatments with high intensity levels favors
CSC proliferation and differentiation in the short term, and consequently fa-
vors future tumor regrowth. The inclusion of a CSC differentiation therapy
in combination with a standard treatment can favor the control of future re-
growth, although the possibility of the remaining CSCs to divide is the key
point in the control.
Therefore, this analysis indicates that making CSC proliferation more dif-
ficult is an important point to consider, especially in the immediate period
after a standard treatment for controlling non-stem cancer cell proliferation.
As stated by Han et al. [38] “maintaining the cells in a quiescent state by
blocking specific receptors and signaling pathways within the CSC niche can
inhibit CSC functions of tumor initiation and metastasis”. Nevertheless, the
current attempts at CSC control are focused on alternatives for CSC elimina-
tion and induction of CSC differentiation [17][38].
Chapter 6
Evolutionary optimization of
cancer treatments in a cancer
stem cell context
In this chapter evolutionary computing for optimizing cancer treatments is
used taking into account the presence and effects of cancer stem cells. When
a standard treatment is applied against non-stem (differentiated) cancer cells,
different effects are present depending on the strategy used to eliminate these
non-stem cancer cells, as explained in the previous chapter. The treatment
strategy implies aspects such as intensity of application, duration and peri-
odicity, with interrelated effects in the regrowth capability when CSCs are
present. Additionally, the best treatment would be the one that, with the less
possible intensity minimizes to a great extent the future regrowth capability
of CSCs. Therefore, it is an optimization problem in which the best treatment
is difficult to foresee, but it can be subject to be optimized with any optimiza-
tion procedure. We selected evolutionary computing as a global search method
and Differential Evolution [79] as a robust evolutionary method. Thus, this
chapter explores the use of Differential Evolution to optimize a treatment in
terms of intensity, duration and periodicity in a CSC context.
6.1 Differential Evolution
Differential Evolution (DE) [79] is a population-based search method. DE
creates new candidate solutions by combining existing ones according to a
simple formula of vector crossover and mutation, and then keeping whichever
candidate solution has the best score or fitness on the optimization problem
at hand. The central idea of the algorithm is the use of difference vectors for
generating perturbations in a population of vectors. This algorithm is specially
suited for optimization problems where possible solutions are defined by a real-
valued vector. The basic DE algorithm is summarized in the pseudo-code of
Algorithm 6.1.1.
Differential Evolution needs a reduced number of parameters to define its
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Algorithm 6.1.1: Differential Evolution(Population)









// must be distinct from each other and x
R←GetRandom(1,n) // the highest possible value n is the
// dimensionality of the problem to be optimized
for each i ∈ 1 : n // Compute individual’s potentially new position
// y = [y1, ...,yn]
do

ri←GetRandom(0,1) // uniformly in open range (0,1)
if ((i = R) || (ri <CR))
yi = x1i +F (x2i −x3i)
else yi = xi
if (f(y)≤ f(x)) x = y // replace x with y in Population
until TerminationCriterion()
return (GetLowestFitness(Population)) // return candidate solution
implementation. The parameters are F or differential weight and CR or cros-
sover probability. The weight factor F (usually in [0,2]) is applied over the
vector resulting from the difference between pairs of vectors (x2 and x3). CR
is the probability of crossing over a given vector of the population (target
vector x) and a “donor” or “mutant” vector created from the weighted differ-
ence of two vectors (x1 +F (x2−x3)) [19]. We used the “binomial” crossover
(specified in the pseudo-code of Algorithm 6.1.1), for defining the value of the
“trial” vector (y) in each vector component or position i [19]. Finally, the in-
dex R guarantees that at least one of the parameters (genes) will be changed
in that generation of the trial solution.
Finally, the selection operator maintains constant the population size. The
fitness of the trial vector (f(y)) and the target vector (f(x)) are compared to
determine which one survives for the next generation: If the new trial vector
yields an equal or lower (better) value of the objective function, it replaces
the corresponding target vector in the next generation; otherwise the target
vector is retained [19]. Thus, the fitness of the best solution of the population
is improved or remains the same through generations.
By combining different mutation and crossover operators various schemes
have been designed. The usual variants or schemes of DE choose the base
vector x1 randomly (variant DE/rand/1/bin, where 1 denotes the number of
differences involved in the construction of the mutant or donor vector and bin
denotes the crossover type) or as the individual with the best fitness found up
to the moment (xbest) (variant DE/best/1/bin). To avoid the high selective
pressure of the latter, we used a tournament to pick the vector x1, which also
allows us to easily establish the selective pressure by means of the tournament
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Figure 6.1: An example of a two-dimensional fitness landscape showing its
contour lines and the process for generating the donor or mutant vector in
Differential Evolution.
size.
Figure 6.1 shows a two dimensional example that illustrates the different
vectors which play a part in the DE search algorithm. As Feoktistov [26]
indicates, the fundamental idea of the algorithm is to adapt the step length
(F (x2−x3)) intrinsically along the evolutionary process. At the beginning of
generations the step length is large, because individuals are far away from each
other. As the evolution goes on, the population converges and the step length
becomes smaller and smaller, providing this way an automatic balance in the
search.
6.2 Examples of treatment strategies
We selected again different scenarios to show the implications of different treat-
ment strategies when CSCs are present. We considered ideal treatments in the
sense that these only kill (non-stem) cancer cells, although this does not change
the reasoning and conclusions drawn from the experiments. The grid size was
64000 (40 sites in each dimension), the simulations begin with the grid full of
healthy cells except the incorporated CSCs, from the beginning, in the inner
area with growth factor. These CSCs correspond to a 5% of the grid size.
We also selected a representative example in which differentiated tumor cells
(DCCs) have a high invasion potential in the surrounding tissue, as we used
g = 5, as in previous chapters. Moreover, since the parameter m determines
the probability of acquisition of hallmarks and consequently the onset of a
tumor behavior, we used m = 1000 to obtain tumor development behaviors
without using a large number of iterations. Nevertheless, the conclusions and
CSC implications commented here are independent of the particular scenario
considered regarding the relevance of the hallmarks.
Figure 6.2 shows an example where continuous treatments are applied in
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Figure 6.2: Evolution of the number of DCCs through time iterations when
continuous treatments that (from time iteration 600) kill 1%, 2% and 3% of
DCCs are applied in every time iteration.
every iteration. The treatments are applied from iteration 600, in order to give
DCCs the opportunity to growth in number. When a treatment that kills 1%
or 2% of DCCs is applied in every time iteration, the number of DCCs is not
controlled enough, ending with an increase of DCCs that will cover the full
grid. On the contrary, when a treatment that kills 3% of the DCCs is applied in
every time iteration, the number of DCCs is controlled to a minimum through
time.
As an opposite strategy, Figure 6.3 shows a run where a discontinuous
and periodic treatment is applied. The treatment kills the 100% of the DCCs
every 600 iterations. The problem with this strategy is that the regrowth of
DCCs is faster with respect to a situation without treatment application, such
as the initial increase of DCCs. The 2D snapshots shown at the bottom of
Figure 6.3 explain again the reason. These snapshots correspond to a central
plane that crosses the grid, and it should be noted that these provide more
information than the 3D representation as these show the internal distribution
of the cells. For example, at t = 3000, all DCCs are eliminated, so there
are empty sites that are filled in few iterations with mostly healthy cells.
Nevertheless, because of these empty sites, the few CSCs (shown with enlarged
size) had more opportunities to proliferate and differentiate, generating a few
DCCs (see snapshots at t= 3020 and t= 3025) that can produce a fast increase
of a tumor bulk. In a normal situation, given the few possibilities for CSCs to
proliferate (the grid is almost full), the increase of DCCs is slower. This fast
increase is well documented in many cancer treatment applications [93][98].
So, this effect must be taken into account in treatment applications, trying to
difficult CSC proliferation and differentiation.
Figure 6.4 now shows an “average” strategy between these two extreme
cases. The treatment is applied periodically, again every 600 time iterations,
but killing only 5% of DCCs in each time iteration. Moreover, the treatment
is maintained during 150 time iterations. Figure 6.4 shows that now, when the
treatment stops after such 150 iterations, the increase of the regrowth is slower
with respect to the previous case. The reason can be guessed looking at the
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Figure 6.3: Evolution of the number of DCCs through time iterations when a
periodic discontinuous treatment is applied (Every 600 time iterations killing
the 100% of the DCCs in such iterations). The bottom part shows 2D snap-
shots of the central part of the grid at given time iterations (Colors: Gray -
healthy cells, Blue - DCCs, Red-enlarged size - CSCs).
snapshots at the bottom of Figure 6.4. For example, the snapshot at t= 3020
shows that the CSCs are immediately surrounded by healthy cells, given the
very few free sites produced as consequence of the low-intensity treatment, so
CSCs had no so many opportunities to proliferate and differentiate as in the
previous case (this behavior was explained in chapters 4 and 5). So, this seems
a good strategy, trying to difficult CSC proliferation through low-intensity
treatments.
Figure 6.5 illustrates the intensity used during each treatment application,
measured as the percentage of DCCs killed in each iteration. This Figure
shows the accumulative treatment intensity as consequence of the application
of previous treatment strategies, that is, the summation of the intensity of the
treatment during the intervals of its application. In Figure 6.5 we considered
the intensities as probabilities of killing a DCC, so these are in the interval
[0,1] in each iteration.
In the cases corresponding to the periodic treatments previously considered,
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Figure 6.4: Evolution of the number of DCCs through time iterations when a
periodic discontinuous treatment is applied (Every 600 time iterations killing
the 5% of the DCCs during the next 150 iterations). The bottom part shows
2D snapshots of the central part of the grid at given time iterations.
logically the accumulative intensity follows a linear progression. With the dis-
continuous treatments, the accumulative intensity is increased in the partic-
ular iterations the treatments are applied. Figure 6.5 and previous Figures
(Figs. 6.2 - 6.4) show the different behaviors in the two features considered
(number of final DCCs and accumulative treatment intensity): The continuous
treatment that kills 3% of DCCs in each iteration has the number of DCCs
controlled at the cost of high treatment intensity. The discontinuous periodic
treatment with high intensity (Figure 6.3) has a lower value in the accumulat-
ive treatment intensity but has a poorer control of the final number of DCCs
(as consequence of the fast regrowth of DCCs). Finally, the periodic treatment
that kills 5% of DCCs in each iteration, maintained during 150 time iterations
(Figure 6.4) has a better control over the final DCCs (with respect to the
previous case, Fig. 6.3) but a higher accumulative intensity. In order to find
out what strategy would be the best regarding these objectives, we applied the
evolutionary methodology to optimize the treatment taking into account such
objectives or measures.
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Figure 6.5: Accumulative treatment intensity across iterations with different
treatment strategies of previous Figures.
6.3 Treatment strategy optimizations
We can first begin with the use of the evolutionary algorithm to try to optimize
a single treatment application. The first test implies the optimization regard-
ing the intensity of application of a conventional treatment (chemotherapy or
radiotherapy) that kills DCCs as well as its duration. We used the previous
scenario with high invasion potential of cells with the hallmark IGI acquired,
with a 5% of incorporated CSCs. Treatments always begin at time iteration
t= 600. The genotypes include the encoding of both parameters (intensity and
duration) in the interval [-1,1], while the encoded values are decoded in the in-
terval [0%,100%] for the intensity of the treatment, meaning that a number of
DCCs corresponding to that percentage are killed in each iteration. The DCCs
subject to be killed are randomly selected. For the duration of the treatment
we used an ample range [0,600] (which corresponds to an interval [0,65 days]),
meaning that the treatment with the encoded intensity of the first parameter
is maintained that number of iterations.
For the fitness function we used a simple formula, which takes into account
two terms: First, the final number of DCCs after a given number of iterations
(100) once the treatment is stopped. Second, the intensity used during the
treatment application. This second aspect is not easy to measure, but we can
assume it is related to the summation of the percentage of DCCs killed in each
iteration (as illustrated in previous examples and Figure 6.5). This means,
for example, that a high-intensity treatment which kills 100% of DCCs in one
iteration is equivalent (regarding the intensity measure) to a treatment that
kills 1% of DCCs during 100 iterations. The fitness is a weighted summation of
both terms (0.01·final number of DCCs + treatment intensity, with the weights
tuned so that both terms have close values in best individuals). Finally, the
fitness of each encoded parameter set is averaged with 5 independent runs of
the multicellular system.
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Figure 6.6: Multicellular system evolution when a best evolved treatment is
applied, with its intensity and duration optimized. Treatments begin in time
iteration t= 600. In the example, the best evolved treatment kills 38% of DCCs
in the next 18 time iterations. A high-intensity treatment that kills the 100%
of DCCs only at t = 600 is included for comparison. Upper part: Evolution
of DCCs through time iterations. Middle part: Evolution of the number of
CSC asymmetric divisions. Bottom Part: 2D snapshots of the central part of
the grid corresponding to the multicellular system evolution at particular time
iterations when the best evolved treatment is applied.
We used DE with a population of 50 individuals, with standard values for
the other parameters in DE: CR= 0.9 and F = 0.9 [78], whereas the size of the
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tournament to choose the base vector was 8% of the population, which implies
a low selective pressure when selecting that vector to disturb (Section 6.1). The
evolutions were run for 50 generations using again a grid size of 64000 sites. For
this test we used the parameters previously commented (g = 5 and m = 1000
while the rest of hallmark parameters were set to their standard values) and,
as indicated, the encoded treatments begin at time iteration t= 600. Because
of the different duration of the encoded treatments, the simulation time of
each treatment is variable. Given the high requirements in processing time for
the simulation of the multicellular system, using an Intel Core i3 processor at
3.33 GHz and 4 Gytes of main memory, the average computing time for each
DE generation was 36 minutes.
Figure 6.6 shows the behavior with one of the best strategies found by the
evolutionary algorithm, with an intensity of 38% and duration of 18 iterations
(1.95 days). The upper part corresponds to the evolution of the number of
DCCs. We included a high-intensity treatment for comparison, which kills the
100% of DCCs only at time iteration t= 600. The middle graph illustrates the
number of CSC asymmetric divisions in both cases, which is increased when
CSCs have more opportunities to proliferate during the treatment adminis-
tration. Finally, the bottom subfigures show again 2D snapshots of central
sections of the grid at three time iterations when the best evolved treatment
was applied. The snapshots show that, even with this treatment intensity
that generates a few empty sites (see snapshot at t = 600) so the surrounding
CSCs can take advantage for their proliferation and differentiation, the main-
tained treatment eliminates those DCCs in the next few iterations. All the
best evolved treatments follow this pattern avoiding high intensities: the av-
erage intensity of the best evolved treatments was 32.3% (standard deviation
5.1) in 10 independent DE runs, while the average duration was 26.4 iterations
(standard deviation 9.3).
In a second test we used DE for the optimization of three parameters of
a treatment: the previous two (intensity and duration), together with the
period of application of the treatment. As in the previous case, the treatment
intensity, once decoded, can vary in the interval [0%,100%]. Now, the period
of application can vary in the interval [0,600], meaning that the treatment
is periodically repeated with the period indicated with the decoded value.
The other parameter, the duration of the treatment in each application, is
dependent on the period of application. This parameter is encoded again in the
interval [-1,1], but decoded taking into account the encoded value of the period
of application. For example, if the encoded value for the period represents 500
time iterations and the encoded value for the duration is 0 (middle value in the
interval [-1,1]), then the duration is 250 time iterations in each application.
The other DE parameters are the same as in the previous test. We used
simulations of the multicellular system with a minimum of 3000 time iterations,
so every encoded treatment strategy is applied several times to determine
the fitness. Given the higher number of time iterations in the evaluation of
each encoded solution, the average computing time per generation is now 237
minutes, using the same population size (50) and computing platform as in
the previous test.
As in the previous case, the fitness is defined as the same weighted sum of
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the intensity of the treatment and the final number of DCCs after 100 time
iterations of its cessation. The first term is measured again as the intensity
used across the whole period since the beginning of the treatment application,
taking into account that all treatments are applied after time iteration t= 600
in order to have an initial and significant increase of DCCs.
Figure 6.7: Multicellular system evolution when a best evolved treatment is
applied, with its period, intensity and duration optimized. Treatments do
not begin before time iteration t = 600. In the example, the best evolved
treatment kills 49% of DCCs during 8 time iterations and a period of 346
iterations (treatment A). A high-intensity treatment that kills the 100% of
DCCs every 600 iterations is included for comparison (treatment B). Upper
part: Evolution of DCCs through time iterations. Bottom Part: Interval of
time iterations enlarged for a more detailed view of the effect of the treatment
strategies on next DCC progression. This bottom Figure also includes the
number of CSC asymmetric divisions with the two treatments.
Figure 6.7 now shows the behavior with one of the best evolved strategies,
with an intensity of 49%, a period of application of 346 (37.5 days) and a
duration of 8 iterations (21 hours). Again, the graph includes, for comparison,
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a high-intensity treatment that kills the 100% of DCCs in only one iteration,
being periodically applied with a period of 600 time iterations. Figure 6.7
includes an enlarged view of a particular interval of the multicellular system
evolution, between time iterations 1700 and 2000, which denotes the same ef-
fect previously explained: A high-intensity treatment promotes CSC prolifera-
tion and differentiation (as shown with the higher number of CSC asymmetric
divisions in the bottom part of Figure 6.7), so there is a posterior high increase
of DCCs. Note that this enlarged view shows that, after the fast increase of
DCCs, their progression is more stable in next iterations. This is because in
the CSC asymmetric divisions the new DCCs acquire randomly one of the five
hallmarks and only the hallmark IGI provides an immediate advantage for
fast proliferation. Thus, more time iterations are necessary so that a sufficient
number of DCCs acquire that hallmark to begin again an increase in their
number. On the contrary, the evolved periodic and discontinuous treatment
makes more difficult CSC differentiation, so the future regrowth of DCCs is
slower and consequently it is easier to control DCC increase.
6.4 Discussion
In this chapter we used the tumor growth model to analyze the implications
of treatment strategies taking into account the presence of CSCs, using evol-
utionary computing to establish the best strategies of treatment applications
considering the regrowth capacity of such CSCs. We emphasize the difference
of our work and aim with respect to standard treatment strategies. For ex-
ample, an usual treatment like FOLFOX4 protocol [43] demonstrated effective-
ness against regrowth in phase II of colon cancer [18]. This is a chemotherapy
treatment in which drugs are used to kill the cancer cells. Mostly two or more
drugs are used in combination which proves to be more effective. In FOLFOX
chemotherapy, drugs used are Fluorouracil 5FU, Folinic acid (Leucovorin) and
Oxaliplatin. Typically the treatment is composed of 12 phases or cycles, each
one 14 days length. These types of protocols were experimentally tested and
tuned to shrink the tumor bulk. Nevertheless, no treatment analyses took
into account, with an exhaustive study, the effect of possible future relapses
(regrowths). So, computational experiments, even with the simplifications
performed, can go a step ahead with respect to in vitro and in vivo analyses,
and additionally allow explaining the reasons of the resultant behaviors.
Since we considered different terms in the fitness, it is obvious that we could
use a multi-objective approach for searching the Pareto Set of non-dominated
individuals regarding, for example, the treatments that minimize the total
intensity applied and the treatments that minimize the final number of DCCs
(with obvious optimal strategies). Nevertheless, we first tackled the problem
with the mono-objective approach to analyze the implications of the presence
of CSCs and the main aspects that can define a treatment strategy.
It is also obvious that other treatment strategies can be considered, such as
applications with increasing or decreasing intensities through time. Although
we used a particular scenario of relevance of hallmarks, and consequently the
treatment parameters are optimized for that scenario, the implications of CSC
presence are general: in contrast with the main current attempts to CSC
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control focused on alternatives for CSC elimination and induction of CSC dif-
ferentiation [17][38], our analyses show that treatments should be maintained
during very few days, avoiding high intensities and, consequently, with longer
periods than the ones used in standard treatments. This is always with the aim
to make more difficult CSC proliferation and consequently their differentiation
in order to minimize their future effect on a possible tumor regrowth.
Chapter 7
Conclusions
We used computational models based on cellular automata and the abstract
model of cancer hallmarks to analyze the emergent behavior of tumor growth
at cellular level. The emergent behavior of growing multiclonal tumors is al-
most impossible to infer intuitively, as commented by Rejniak and Anderson
[80], so the simulation tools help to inspect the emergent behavior under differ-
ent conditions. Or, as indicated by Kansal et al. [48], if tumors do not behave
as random, disorganized and diffuse cell masses, then “the growing tumor and
not only the single cell must be investigated and treated as a self-organizing
dynamic system”, which, according the authors cannot be done with currently
available in vitro/in vivo models or common mathematical approaches. There
is a need for novel computational models to simulate the mechanistic com-
plexity of solid tumor growth and invasion, like CA, that can easily model the
emergent nature of the process [48]. We used CA for the modeling because,
given the interrelations among the different hallmarks, in addition to the de-
pendence of the hallmarks on some parameters, the modeling at cellular level
with CA makes easy the study of the final emergent behavior, which cannot
be foreseen in many cases. Thus, we can easily analyze the dependence of the
emergent behavior on hallmarks and defining parameters.
Another advantage of the “in silico” models is that we can run experiments
that would be too expensive and time-consuming to carry out in the lab [88].
Moreover, as indicated by Savage [88] regarding the complexity of cancer “Re-
searchers have tended to focus on genes and proteins, but to understand and
fight the disease, it must be viewed as a system, rather than merely as a set
of cellular activities”. Thus, “the recent focus on genetics and pathways in in-
dividual cells has caused many researchers to neglect the systemic view” [88].
The simulations based on CA are within this idea emphasized by Savage [88],
as the model permits an analysis and view of the system working with dif-
ferent levels of abstraction or with the focus on particular simulation aspects.
Moreover, the abstract model of cancer hallmarks is the ideal one for the study
of the multicellular system in terms of behavioral characterization, which was
our objective, rather than particularizing in a cancer type and without the
need of characterization of the molecular and gene pathways involved in the
acquisition of the hallmarks.
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We must point out a comment about the implications of the use of the hall-
mark abstract model considered here. Loeb and Loeb [55] indicated that “The
mutator phenotype hypothesis proposes that the intrinsic genetic instability
of cancer cells drives tumorigenesis by producing a pool of mutations, some of
which confer a selective advantage, allowing cells to proliferate under adverse
conditions. Others have suggested, however, that increased mutagenesis is not
required to produce the multiple mutations observed in cancers, and hypothes-
ize that selection pressures and clonal expansion are the major driving forces
in tumorigenesis”. We worked with the abstract model of the hallmarks, inde-
pendently of those reasons for acquiring the corresponding hallmarks, as it can
be an oncogene-induced mitotic stress [59]. But the hallmark abstraction does
not take into account that, when a hallmark is acquired, there can be random
mutations which were not selected (but can be advantageous in a posterior
phase to confer resistance to treatments), or whether the mutations corres-
pond to expanded mutations as result of ongoing selection to confer the cells
with such mutations a growth capability. Our interest here was to isolate the
hallmarks to study their effect in advantageous situations (that lead to tumor
growth), and, with this knowledge, analyze the combined effect incorporat-
ing also a CSC context. These advantageous situations could be interpreted
as clonal selection, but it is because the hallmarks provide the advantage in
the scenarios chosen. However, the model does not provide insight about the
different reasons to acquire the mutations that define the hallmarks.
As indicated by Rejniak and Anderson [80], “by necessity, many of the
cancer models were general, phenomenological, and not specific to a type of
cancer and therefore were plagued by a lack of experimental data to both para-
meterize and validate. That is not to say they were not useful”. Given the
simplifications, the modeling considered in the thesis was oriented to mimic the
development of multicellular spheroids of tumor cells and not to a particular
cancer type. As Spencer et al. point out “When modelling a complex biological
process, it is always necessary to make simplifying assumptions” [94], so we
can study cancer at the cell population level, modeling tumors as evolving eco-
systems and without incorporating every known piece of molecular cell biology
relating to cancer [94]. In the simulation, each cell has an associated genome
which determines the different cancer hallmarks acquired by mutations. These
hallmarks and their associated parameters define cell states and cell mitotic
behaviors, so different dynamics can emerge in the multicellular system. We
focused in the thesis on how the cellular automata simulating tool can provide
a model for analyzing tumor growth behavior under different conditions, such
as behavioral regime transitions between states with predominance of healthy
or cancer cells and the dependence of the emergent tumor growth behavior on
each individual hallmark, studying their relative importance in tumor devel-
opment.
With the simulation tool we performed several tests. First, we tested
whether the emergent behavior is independent of the initial conditions of the
cellular environment, regarding its initial available free space (Chapter 3).
The emergent behavior depended only on the parameters associated with the
hallmarks, although the time iterations applied to obtain stable behaviors are
dependent of the starting free space. Additionally, the experimentation per-
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formed showed that the effect of elimination of hallmarks is different depend-
ing on the main advantage, with respect to healthy cells, of the cancer cells to
propagate, allowing the quantitative analysis of the relevance of the hallmarks
in different scenarios. As mentioned in Chapter 3, Hanahan and Weinberg
[40] stated that, in addition to providing a solid basis for cancer research,
the hallmarks have served to identify certain cell functions that have become
therapeutic targets with the idea that simultaneous targeting of two or more
hallmark pathways may be a more effective approach to therapy. Along this
line, our study in Chapter 3 about the relative importance of the hallmarks
in tumor cells proliferation indicates the importance of targeting therapies to
the genetic networks and molecular pathways that control such most relevant
hallmarks in each environmental multicellular system situation.
Moreover, we focused on the analysis of the effect of killing cancer cells,
inspecting the time evolution of the multicellular system under such conditions
and the possible behavioral transitions between the predominance of cancer
and healthy cells (Chapter 3, Section 4). For example, the model shows that,
in situations where cells at the tumor boundary drive tumor expansion, there
are no significant differences between the consideration of killing all cancer cells
and killing only cancer cells at the boundary or the tumor. As remarked in
Chapter 3, that analysis represents an alternative to the “in-vitro” experiments
focused on the study of the comparative effects of different drugs or drug
combinations [22][63], since it indicates that these “in-vitro” studies should
also search for possible behavior transitions when drugs are applied.
Later, the previously commented conditions defined by the relative preval-
ence of different hallmarks, were incorporated in the simulation of cancer stem
cells (Chapter 4). The CSCs can regenerate the proliferation of cancer cells
when the non-stem cancer cells, with the appropriate hallmarks acquired, find
advantageous scenarios. The simulations showed how the increase of non-stem
cancer cells is faster after a treatment that targets differentiated cancer cells,
since CSCs have more opportunities to differentiate. This is in agreement with
the clinical observations describing increased growth speed and enhanced in-
vasion in the relapsing malignancy [93]. The importance of the simulations is
that these provide the reason and an easy explanation of the faster regrowth
behavior.
Moreover, the effects of different treatment strategies were analyzed by
using continuous low-intensity treatments and periodic high-intensity treat-
ments. The first alternative presents an advantage since continuous low-
intensity treatment does not favor CSC proliferation and differentiation, al-
lowing an easy control of a possible future tumor regrowth. On the other
hand, the discontinuous periodic treatments with high intensity levels favor
CSC proliferation and differentiation in the short term, and consequently fa-
vors a possible future tumor regrowth. Therefore, the analysis performed in
the thesis indicates that making CSC proliferation more difficult is a key point
to consider, especially in the immediate period after a standard treatment in
order to prevent the spread of non-stem cancer cells.
The analyses of the treatment strategies applied in a cancer stem cell con-
text (Chapter 5) indicate several key aspects:
1. Using only standard treatments, which only eliminate rapid prolifer-
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ating non-stem cancer cells, not only do not stop possible future regrowths
as consequence of the presence of CSCs, but facilitates that the regrowth is
faster.
2. A differentiation therapy for CSCs in combination with a standard
treatment can better control the future regrowth, but the relative timing of
the two treatment strategies is determinant, since CSC differentiation produces
non-stem cancer cells that can promote rapid tumor proliferations.
3. The ideal treatment should difficult CSC proliferation, especially after
the immediate application of a standard treatment, and the analyses indicate
that a low-intensity standard treatment is better for making more difficult CSC
proliferation and differentiation. As stated by Enderling and Hahnfeldt [25]
“If detected early, tumors could potentially be maintained at a non-advancing
equilibrium by reinforcing the ability of non-stem cells to competitively sup-
press CSC proliferation”. So, as indicated by Han et al. [38], targeting CSC
niche and the quiescent state of CSCs is a therapeutic possibility since “Main-
taining the cells in a quiescent state by blocking specific receptors and signaling
pathways within the CSC niche can inhibit CSC functions of tumor initiation
and metastasis”. Our analyses show that this is one of the most important
factors to control, which was not intensively considered.
Finally, we used evolutionary computing to analyze the implications of
treatment strategies taking into account the presence of CSCs (Chapter 6).
In this way, we determined the best strategies of treatment applications in
terms of intensity, duration and periodicity considering the regrowth capacity
of CSCs. We considered that the best treatment is the one that, with the less
possible intensity minimizes to a great extent the future regrowth capability
of CSCs. The intensity was measured as the summation of the percentage of
DCCs killed in each iteration. The analyses showed that, in order to make more
difficult CSC proliferation and consequently their differentiation, treatments
with high intensities should be avoided. These ones promote CSC proliferation
and differentiation, making more difficult the control of the final number of
DCCs as consequence of the fast regrowth of these DCCs. The best evolved
treatments follow this pattern avoiding high intensities, always with the ob-
jective to avoid CSC proliferation and therefore their differentiation in order
to minimize their future effect on a possible tumor recurrence. Moreover, the
optimized treatments correspond to those maintained during very few days
and with longer periods than the ones used in standard treatments.
The work done in this thesis could be further developed in a number of
ways. One of them is extending the computational model to consider angiogen-
esis and cell migration (translation of cells from one location to another). We
have not considered these two aspects because we analyzed only the avascu-
lar phase. For example, the inclusion of metastasis and motility for CSCs
could provide insights about other aspects, such as possible morphologies of
the growing tumor, as studied, for example, in the work of Sottoriva et al. [93]
in order to analyze the different infiltrative morphologies beyond the borders
of the main tumor mass.
Another topic to explore in more detail is the use of evolutionary multi-
objective algorithms for treatment optimization, as explained in Chapter 6.
In this chapter we used mono-objective optimization for optimizing cancer
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treatments in terms of intensity, duration and periodicity in a CSC context.
This can be improved using a multi-objective approach for searching the Pareto
Set of non-dominated individuals regarding the treatments that minimize the
total intensity applied as well as the final number of DCCs.
Finally, little is known about the theoretical aspects of the behavior of
the multicellular system, in terms of information theory. Studies should be
performed on the situation once a tumor growth behavior has been obtained,
at its origin, and at the intermediate stages. The characterization of the dif-
ferent behaviors could be done using a qualitative and quantitative study of
the time evolution of cell colonies in the different behavioral regimes. For the
quantitative analysis, classic information theory measures could be used, such
as entropy and mutual information, through the study of the time evolution of
the cells in the lattice environment, taking into account the state distribution
(related to the presence of hallmarks) of cells in the lattice and the time evol-
ution of such distributions. This analysis will be especially interesting under
the threshold conditions that determine the outcome of different behavioral
regimes, that is, these conditions will determine the presence or not of a tu-
mor. So, this analysis would allow us to thoroughly study the dynamic process
in the frontier conditions that lead to cancer.
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Appendix B
The graphical user interface
All the simulations and options commented in the thesis were incorporated in a
simulation environment for the testing of the experiments. The whole project
was programmed in the C# language using the Microsoft Visual Studio 2008
environment. Figure B.1 shows the main interface window of the environment.
The interface was divided in two main parts: Simulation and Evolution.
In the Simulation panel the user can set the parameters of the simulation.
Below the list of parameters is presented:
• Simulation parameters panel:
– Grid size: it represents the total number of the cells of the grid.
– Max iters: it represents the maximum number of iterations of the
Cellular Automata. The simulation ends before this iteration if the
event queue is empty.
• Hallmark parameters panel: in this panel the parameters that control the
hallmarks can be set. The default parameters are presented as default
values.
• Visualization panel: this panel has different options that allow the user
set visual information. The user can set whether the tumor growth
is displayed step by step (the graph is updated every 50 iterations by
default) or at the end of the simulation. Moreover, in this panel, the
user can save in a file an image in 3-D or 2-D in “PNG” format (figures
B.2 and B.3). In the 3-D view, each cell is rendered as a small cube.
The cube is colored according to the “genotype” of the cell it represents.
There are 32 colors corresponding with the 32 possible combinations of
mutations (hallmarks acquired) in the “genotype”.
Once the parameters are filled the Run button is pressed to begin the
simulation.
At the right side of the main window, the Evolution environment is located.
In the panel Differential Evolution parameters the user can set the different
parameters of the Differential Evolution optimization method. Here the list of
parameters is presented:
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• Population Size: the size of the population (must be greater than 4).
• Generations: optimization is ended by the specified number of genera-
tions set by user in this field.
• Grid size: it represents the total number of the cells of the grid.
• Max iters CA: it represents the maximum iterations of the Cellular Auto-
maton.
• Num Evaluations CA: the number of evaluations applied to each indi-
vidual of the population. Given the stochastic nature in each run of the
cellular automaton and consequently in the fitness evolution, the fitness
is averaged with that number of independent evaluations of the cellular
automaton.
• DE Crossover probability (CR): the crossover probability parameter.
• DE Weight Factor (F): the differential weight parameter.
• Fitness Function. The user can select different objective functions to
optimize: cancerous-healthy cells difference, number of total cells, aver-
age distance to the center, number of healthy cells, number of cancerous
cells. In the thesis, only the fitness commented in Chapter 6 was used
to optimize treatment applications.
• Type: the user can select maximize or minimize.
Figure B.1: Main panel of the simulator.
Figures B.2 and B.3 present the windows of the simulator that show the
final result of the multicellular system after a cellular automaton run with a
3D and 2D representation respectively. To view the final grid state from a
different angle the user can use the slider control Rotations (X,Y,Z) located
at the lower part of the window. Moreover, for a better visualization, the user
can zoom in by clicking the control slider Zoom and also can choose the type
of cells displayed (all cells, only cancer cells or only healthy cells).
The environment allows to see graphically the evolution over time of dif-
ferent parameters as Figure B.4 shows. In the Cellular system time evolution
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Figure B.2: Window of the simulator, that shows the final grid state with a
3D representation.
Figure B.3: Window of the simulator, that shows the final grid state with a
2D representation (plane that crosses the center of the grid).
panel the evolution over time of the hallmarks is shown (number of hallmarks
acquired in all the cells) is displayed. In addition, if the checkbox Show All is
checked then the evolution of the cancer and healthy cells is also shown. In the
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Evolution graphics panel the evolution of the best fitness and average fitness
over generations is displayed.
Figure B.4: Window of the simulator, that shows the evolution of hallmarks
and cell types (associated to the Simulation part) and the evolution of the best
and average fitness (associated with the Evolution part).
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In accordance with the Regulations of the Ph.D.
studies passed by the Governing Council of the
University of A Corun˜a at its meeting of July
17, 2012, it is reproduced below a summary of
this thesis in Spanish.
C.1 Motivacio´n
En esta tesis se ha realizado un modelado del crecimiento tumoral, consider-
ando e´ste consecuencia emergente de las interacciones entre las ce´lulas y su
entorno. El modelado se ha considerado en el nivel de comportamiento ce-
lular, modelando los procesos de mitosis y muerte celular en funcio´n de la
adquisicio´n de una serie de rasgos caracter´ısticos del ca´ncer (hallmarks) y del
entorno inmediato de cada ce´lula.
El ca´ncer es una enfermedad gene´tica que, en el paradigma esta´ndar,
aparece como consecuencia de diversas mutaciones en ce´lulas soma´ticas [33].
Estas mutaciones alteran el control de proliferacio´n de las ce´lulas que desem-
boca en una divisio´n celular descontrolada. Hanahan y Weinberg describieron
las diferencias fenot´ıpicas entre las ce´lulas sanas y las cancerosas en un art´ıculo
titulado “The Hallmarks of Cancer” [39] y su revisio´n en 2011 [40]. Las seis
alteraciones esenciales en la fisiolog´ıa celular que colectivamente dictaminan el
crecimiento maligno son: autosuficiencia en las sen˜ales de crecimiento, insens-
ibilidad a las sen˜ales inhibidoras del crecimiento, la evasio´n de la muerte celular
programada (apoptosis), potencial de replicacio´n ilimitado, angioge´nesis sos-
tenida, e invasio´n de tejidos y meta´stasis, junto a la propiedad de inestabilidad
gene´tica que facilita la adquisicio´n de los rasgos caracter´ısticos.
Para el modelado hemos considerado la herramienta de Auto´mata Celu-
lar (AC), herramienta introducida por von Neumann para estudiar procesos
de auto-replicacio´n, y que ha sido aplicada adema´s para estudiar el com-
portamiento emergente junto con la caracterizacio´n de sistemas complejos
[2][46][51][52]. Un AC esta´ formado por un espacio de n dimensiones dividido
en un conjunto de celdas, en el que cada una de e´stas puede encontrarse en dos
o ma´s estados. Las reglas que definen el AC determinan cua´l es el siguiente
estado de cada celda, en funcio´n del valor de las celdas consideradas en su “vec-
indad”. Como indica Ilachinski [46], los ACs han sido el foco de atencio´n por
su habilidad de generar un amplio espectro de patrones de comportamiento en
funcio´n de conjuntos de reglas definitorias relativamente simples, y adema´s han
mostrado la capacidad de capturar caracter´ısticas esenciales de comportami-
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entos cooperativos auto-organizativos complejos observados en sistemas reales.
La aproximacio´n tradicional para modelar el crecimiento tumoral ha sido
el uso de ecuaciones diferenciales para definir el estado previo al crecimiento
vascular, e incluso en el estado de creacio´n de nuevos vasos sangu´ıneos. Como
indican Patel y Nagl [76], la utilizacio´n de ecuaciones diferenciales asume
automa´ticamente que el estado actual del sistema es una consecuencia de
su estado global previo. En realidad, una ce´lula individual se comporta de
acuerdo a su inmediata localidad, no de acuerdo con el estado general del
tumor, y los entornos locales son diferentes. O, como indican Wodarz y Ko-
marova [103], entre las ventajas del uso de ecuaciones diferenciales ordinarias
esta´ su simplicidad. Las desventajas incluyen la ausencia de detalle. Por ejem-
plo, no se pueden describir interacciones espaciales, imponiendo la asuncio´n
de interacciones del tipo masa-accio´n. Aun utilizando ecuaciones diferenciales
parciales, estas aproximaciones tienden a representar las ce´lulas tumorales de
un modo colectivo, utilizando t´ıpicamente un te´rmino de proliferacio´n y un
te´rmino de muerte celular, incluyendo funcionalidades espec´ıficas opcionales
como la interaccio´n de las ce´lulas tumorales con su entorno local. Adema´s,
muchos modelos de este tipo presuponen que todas las ce´lulas cancerosas han
adquirido los mismos hallmarks [24]. Por contra, e´ste no es el caso de las
aproximaciones con auto´matas celulares, en las cuales el estado de cada ce´lula
se define en funcio´n de su entorno o vecindad local.
La tesis considera el modelo de “hallmarks” para definir el estado de cada
ce´lula, situa´ndonos por tanto en el estudio del comportamiento a nivel celular,
sin entrar en los niveles inferiores molecular, gene´tico o epigene´tico. En la in-
tensa investigacio´n en modelado de ca´ncer, como indica Savage [88], los invest-
igadores han tenido una tendencia a centrarse en los genes y las prote´ınas pero,
para entender y combatir la enfermedad, debe ser vista como un sistema, en
lugar de simplemente como un conjunto de actividades celulares. As´ı, el autor
indica que el reciente e´nfasis en la gene´tica y en las v´ıas de sen˜alizacio´n celular
en las ce´lulas individuales ha causado que muchos investigadores olviden la
visio´n siste´mica.
Teniendo en cuenta estas consideraciones se ha utilizado la abstraccio´n que
representa la presencia de los hallmarks adquiridos por las ce´lulas, que son a su
vez consecuencia de los niveles inferiores (por ejemplo diversas mutaciones en
oncogenes y genes supresores de tumores en las divisiones celulares), pero con
una visio´n a nivel de interacciones celulares, permitiendo esa visio´n ma´s integ-
radora comentada por Savage. Pero dadas las interacciones entre los diferentes
hallmarks, y la dependencia de estos de sus para´metros definitorios (probab-
ilidades de aplicacio´n, longitud inicial telo´meros, . . . ), el comportamiento que
se obtiene en el sistema multicelular es imposible de inferir intuitivamente o
anal´ıticamente. Es decir, estamos ante un ejemplo de comportamiento emer-
gente, en el cual, aun conociendo las reglas de comportamiento e interacciones
locales de los elementos constitutivos del sistema, no es posible inferir a priori el
comportamiento resultante. Sin embargo, la simulacio´n del comportamiento
en cada ce´lula, definido por un AC en funcio´n de los hallmarks adquiridos
en cada ce´lula, permite el ana´lisis detallado de los posibles comportamientos
emergentes mediante la iteracio´n continua del AC a lo largo del tiempo y en
cada ce´lula individual.
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Como indican Basanta y colaboradores [11], los modelos informa´ticos con-
stituyen una herramienta exploratoria complementaria dada la complejidad de
los procesos biolo´gicos subyacentes y los requerimientos de tiempo involucrados
en los experimentos biolo´gicos tradicionales, a pesar incluso de que tales mod-
elos computacionales son necesariamente una simplificacio´n de la realidad. La
biolog´ıa computacional es una aproximacio´n u´til para el ana´lisis de la dina´mica
evolutiva de los diferentes fenotipos en un tumor. En esta l´ınea de utilizacio´n
de las simulaciones en biolog´ıa computacional se inscribe nuestro trabajo.
C.2 Estructura de las tesis
En el primer cap´ıtulo introductorio se ha explicado la motivacio´n de la tesis, los
trabajos previos con auto´matas celulares en modelado de crecimiento tumoral
y, particularmente, los pocos trabajos que han usado el modelo de hallmarks en
la modelizacio´n. Se explican de modo somero los aspectos ma´s representativos
de la biolog´ıa del ca´ncer, comentando los detalles ma´s relevantes de cara a
nuestra modelizacio´n, la explicacio´n de los diferentes hallmarks considerados en
la misma as´ı como aspectos ba´sicos sobre el ciclo celular y sobre rutas celulares.
Se realiza tambie´n una introduccio´n a la teor´ıa de “Ce´lulas madre del ca´ncer”
(CMC), que sugiere que una minor´ıa de ce´lulas (CMC) es la responsable del
desarrollo del inicio de un tumor y de su habilidad para metastizar y reaparecer
(recidiva). El comportamiento y consecuencias de la presencia de CMC sera´
incorporado en la modelizacio´n realizada en la tesis.
El segundo cap´ıtulo describe los detalles del modelado realizado con ACs
para la simulacio´n del comportamiento mito´tico y apopto´tico en cada ce´lula.
Se ha partido del modelo de eventos introducido por Abbot y colaboradores
[1], aunque nuestro objetivo ha sido diferente al de esos autores, cuyo intere´s
fue determinar las secuencias ma´s probables de adquisicio´n de hallmarks que
terminan en un crecimiento tumoral. Nuestro intere´s se ha centrado siempre
en el ana´lisis de los diferentes comportamientos que se pueden obtener en el sis-
tema multicelular. Se han considerado en la tesis cinco rasgos caracter´ısticos:
autosuficiencia en las sen˜ales de crecimiento, insensibilidad a las sen˜ales inhi-
bidoras del crecimiento, la evasio´n del mecanismo de apoptosis, potencial de
replicacio´n ilimitado e inestabilidad gene´tica. No se han considerado los ras-
gos caracter´ısticos de angioge´nesis y meta´stasis, ya que nuestra modelizacio´n
siempre se ha focalizado en la primera etapa de crecimiento tumoral avascular.
Los hallmarks esta´n adema´s determinados por para´metros definitorios que se
explican en el cap´ıtulo. La simulacio´n utiliza un modelo de ret´ıcula en 3D
para situar espacialmente las ce´lulas, y cada una de e´stas tiene asociado un
“genoma” artificial que determina si alguno de esos hallmarks considerados ha
sido adquirido como consecuencia de mutaciones en la divisio´n celular.
El tercer cap´ıtulo estudia la aparicio´n de posibles comportamientos en es-
cenarios concretos que determinan la preponderancia de unos hallmarks sobre
otros. Se eligen siempre escenarios caracter´ısticos que conllevan un crecimi-
ento tumoral. Se estudia y analiza la dependencia del comportamiento frente
a condiciones de partida como el nu´mero de ce´lulas iniciales consideradas en
la ret´ıcula o el taman˜o de ret´ıcula utilizado en la simulacio´n. Se analiza el
efecto de los principales para´metros que definen cada rasgo caracter´ıstico en
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el comportamiento emergente, analizando la interdependencia entre diferentes
hallmarks en el comportamiento final. Igualmente, se analiza la importancia
relativa que puede tener un rasgo caracter´ıstico para obtener un comportami-
ento final de crecimiento tumoral, adema´s del ana´lisis de posibles transiciones
en el comportamiento emergente cuando un agente terape´utico destruye ce´lulas
cancerosas (consideradas como tales cuando adquieren algu´n hallmark).
El cuarto cap´ıtulo incorpora la modelizacio´n de Ce´lulas Madre del Ca´ncer.
Las CMC tienen la capacidad de autorenovacio´n y regeneracio´n del tumor
[34][98]. Si los tratamientos del ca´ncer no destruyen adecuadamente suficientes
ce´lulas madre cancerosas (como los tratamientos esta´ndar actuales), el tumor
puede reaparecer. Se ha analizado el comportamiento del crecimiento del tu-
mor cuando las CMC se consideran en diferentes situaciones ambientales (que
inducen la adquisicio´n de diferentes hallmarks). El cap´ıtulo quinto analiza,
en un contexto de presencia de CMC, diferentes estrategias de aplicacio´n de
tratamientos teniendo en consideracio´n la capacidad de las CMC de regenerar
un nuevo crecimiento futuro del tumor (recidiva).
Finalmente, el sexto cap´ıtulo considera la utilizacio´n de computacio´n evol-
utiva para la optimizacio´n de un tratamiento contra ce´lulas cancerosas diferen-
ciadas (no CMC), teniendo de nuevo en cuenta el efecto futuro de regeneracio´n
del tumor por la presencia de las CMC. Se ha utilizado Evolucio´n Diferencial
[79] como me´todo evolutivo robusto y contrastado en el campo, y se ha aplic-
ado para la optimizacio´n de los tratamientos en cuanto a su periodo, intensidad
y duracio´n.
C.3 Conclusiones principales
Con la herramienta de simulacio´n se han realizado diferentes pruebas. Primero,
se ha chequeado si el comportamiento emergente es independiente de las con-
diciones iniciales del entorno celular en cuanto a su espacio libre disponible
(cap´ıtulo 3). El comportamiento emergente depende solo de los para´metros
asociados a los hallmarks, aunque las iteraciones temporales necesarias para
obtener comportamientos estables dependen de esa condicio´n inicial. Adema´s,
la experimentacio´n muestra que el efecto de eliminacio´n de los hallmarks es
diferente dependiendo de la principal ventaja, con respecto a ce´lulas sanas, de
las ce´lulas cancerosas para su proliferacio´n, permitiendo un ana´lisis cuantitat-
ivo de la relevancia relativa de los hallmarks en diferentes escenarios. Como se
indico´ en el cap´ıtulo 3, Hanahan y Weinberg [40] determinaron que, adema´s
de proveer una base so´lida para la investigacio´n en ca´ncer, los hallmarks han
servido para identificar ciertas funciones celulares que se han convertido en di-
anas terape´uticas con la idea de que atacar simulta´neamente dos o ma´s v´ıas de
sen˜alizacio´n celular puede ser un me´todo ma´s efectivo de terapia. En esta l´ınea,
el estudio en el cap´ıtulo 3 sobre la importancia relativa de los hallmarks en la
proliferacio´n de las ce´lulas tumorales indica la importancia de terapias cuyas
dianas sean las rutas moleculares y gene´ticas que controlan tales hallmarks
ma´s relevantes en cada situacio´n ambiental del sistema multicelular. Butler
[14], tomando como base nuestro trabajo, ha experimentado con la eliminacio´n
de los hallmarks en pares, tripletas y grupos de cuatro, tambie´n abstrayendo
la eliminacio´n de hallmarks por los efectos de drogas espec´ıficas y encontrando
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que en algu´n caso la combinacio´n incluso potenciaba el crecimiento, aunque
en general, a ma´s tratamientos aplicados, el crecimiento disminu´ıa.
En el ana´lisis de las posibles transiciones de comportamiento al eliminar
ce´lulas cancerosas, el modelo muestra que, en situaciones en las cuales la zona
exterior del tumor dirige la expansio´n del mismo, no hay diferencias signi-
ficativas entre la eliminacio´n de cualquier ce´lula cancerosa en el tumor y solo
aque´llas del contorno exterior. Este ana´lisis representa adema´s una alternativa
a los experimentos in-vitro focalizados en el estudio de los efectos comparat-
ivos de diferentes drogas o combinaciones de e´stas [22][63], dado que indica
que estos estudios in-vitro deben buscar tambie´n por posibles transiciones de
comportamiento cuando se aplican diferentes drogas.
Cuando se incluye la simulacio´n de CMC (cap´ıtulo 4), el modelado muestra
co´mo las CMC pueden regenerar un crecimiento tumoral cuando las ce´lulas
cancerosas diferenciadas (no CMC), con los hallmarks apropiados, encuen-
tran escenarios ventajosos. Las simulaciones mostraron co´mo el incremento
de ce´lulas cancerosas diferenciadas es ma´s ra´pido despue´s de un tratamiento
que ataca a esas ce´lulas diferenciadas, dado que las CMC tienen ma´s opor-
tunidades para diferenciarse. Esto esta´ en consonancia con las observaciones
cl´ınicas que describen una regeneracio´n posterior ma´s ra´pida del tumor y una
invasio´n acentuada de esa recidiva [93]. La importancia de las simulaciones es
que e´stas proveen la explicacio´n sencilla en el ana´lisis de ese comportamiento
de regeneracio´n ma´s ra´pido del tumor.
El estudio de los efectos de diferentes estrategias de tratamientos, en el
contexto de presencia de CMC, indica que la alternativa de tratamientos con-
tinuos de baja intensidad presenta una ventaja al no favorecer la proliferacio´n
y diferenciacio´n de las CMC, lo que permite un control ma´s fa´cil del posible
recrecimiento futuro. Por contra, la aplicacio´n de tratamientos perio´dicos y
discontinuos con altas intensidades favorece la proliferacio´n y diferenciacio´n de
las CMC en el futuro inmediato y, consecuentemente, favorecen el posible re-
crecimiento futuro del tumor. Por tanto, el ana´lisis realizado en la tesis indica
que dificultar la proliferacio´n de las CMC es un punto importante a considerar,
especialmente en el periodo inmediato despue´s de un tratamiento esta´ndar de
cara a prevenir la expansio´n de ce´lulas tumorales diferenciadas.
Los ana´lisis de las estrategias de tratamientos aplicados en el contexto de
presencia de CMC (cap´ıtulo 5) indican varios puntos clave:
1. La utilizacio´n de u´nicamente tratamientos esta´ndar, que solo eliminan
ce´lulas diferenciadas que proliferan ra´pidamente, no solo elimina la posibilidad
de posibles recrecimientos futuros como consecuencia de las CMC, sino que
adema´s facilita que la recidiva sea ma´s ra´pida.
2. Un “tratamiento de diferenciacio´n” de CMC en combinacio´n con un
tratamiento esta´ndar puede controlar mejor el recrecimiento futuro, pero la
planificacio´n temporal de ambas estrategias es determinante, dado que la difer-
enciacio´n de CMC produce ce´lulas cancerosas diferenciadas que pueden promo-
cionar ra´pidas proliferaciones de un tumor.
3. Finalmente, el tratamiento ideal deber´ıa dificultar la proliferacio´n de
CMC, especialmente despue´s de la aplicacio´n inmediata de un tratamiento
esta´ndar, y el ana´lisis realizado indica que un tratamiento esta´ndar de baja
intensidad es mejor para dificultar la proliferacio´n y diferenciacio´n de las CMC.
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Como indicaron Enderling y Hahnfeldt [25] “Si se detectan pronto, los tumores
se pueden mantener potencialmente en un equilibrio de no avance por medio
del reforzamiento de la habilidad de las ce´lulas cancerosas diferenciadas de
suprimir competitivamente la proliferacio´n de las CMC”. Por tanto, como han
indicado Han y col. [38], atacando el nicho de las CMC y el estado quiescente
de e´stas es una posibilidad terape´utica ya que “Manteniendo las ce´lulas en
un estado quiescente por medio del bloqueo de receptores espec´ıficos y rutas
metabo´licas en el nicho de las CMC puede inhibir las funciones de iniciacio´n
tumoral y meta´stasis de las CMC”. Nuestros ana´lisis muestran que e´ste es
uno de los factores ma´s importantes a controlar y que no ha sido considerado
intensivamente.
Finalmente, al utilizar computacio´n evolutiva para la optimizacio´n de las
estrategias de aplicacio´n de un tratamiento en presencia de CMC (cap´ıtulo
6), teniendo en cuenta que la mejor estrategia de aplicacio´n de un tratamiento
esta´ndar es aque´lla que, con la menor intensidad posible minimiza en gran me-
dida la futura capacidad de recrecimiento de las CMC, el ana´lisis realizado in-
dico´ que, para dificultar la proliferacio´n y diferenciacio´n de las CMC, se deben
evitar los tratamientos de alta intensidad. Estos promueven la proliferacio´n
y diferenciacio´n de las CMC, haciendo ma´s dif´ıcil el control del nu´mero final
de ce´lulas cancerosas diferenciadas como consecuencia de la capacidad de re-
crecimiento ra´pido de e´stas. Los tratamientos optimizados mediante evolucio´n
simulada (para cada escenario particular) siguen este patro´n de evitar altas
intensidades, siempre con el objetivo de evitar la proliferacio´n de las CMC y,
por tanto, su diferenciacio´n de cara a minimizar su futuro efecto de posible
reaparicio´n de un tumor. Adema´s, los tratamientos optimizados especifican
intervalos de mantenimiento de pocos d´ıas y con periodos de aplicacio´n ma´s
espaciados que los de los tratamientos esta´ndar.
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